,General Information,Business:,Industry:,Employees:,Founded:,Contact Information,Address,Phone Number,Web Address,View Prospectus:,Financial Information,Market Cap,Revenues,Net Income,IPO Profile,Symbol,Exchange,Shares (millions):,Price range,Est. $ Volume,Manager / Joint Managers,CO-Managers,Expected To Trade:,Status:,Quiet Period Expiration Date:,Lock-Up Period Expiration Date:,SCOOP Rating,Rating Change
0,,"Datadog is the monitoring and analytics platform for developers, IT operations teams and business users in the cloud age. Our SaaS platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide unified, real-time observability of our customers’ entire technology stack. Datadog is used by organizations of all sizes and across a wide range of industries to enable digital transformation and cloud migration, drive collaboration among development, operations and business teams, accelerate time to market for applications, reduce time to problem resolution, understand user behavior and track key business metrics.",PREPACKAGED SOFTWARE,1212,2010,,"620 8th Avenue, 45th Floor, New York, NY 10018, US",(866) 329-4466,http://www.datadog.com,Datadog,,$7245.9mil,$266.0 mil (last 12 months),$-24.7 mil (last 12 months),,DDOG,NASDAQ,24.0,$27.00 - $27.00,$648.0 mil,Morgan Stanley/ Goldman Sachs/ J.P. Morgan/ Credit Suisse,Barclays/ Jefferies/ RBC Capital Markets/ JMP Securities/ Raymond James/ Stifel/ William Blair/ Needham,9/19/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
1,,"Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA.",MEDICAL LABORATORIES,114,2002,,"1261 Liberty Way, Suite C, Vista, CA 92081, US",(760) 560-1501,http://www.exagen.com,Exagen,,$168.5mil,$37.6 mil (last 12 months),$-18.5 mil (last 12 months),,XGN,NASDAQ,3.6,$14.00 - $14.00,$50.0 mil,Cowen/ Cantor/ William Blair,-,9/19/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
2,,"Ping is pioneering Intelligent Identity. We enable secure access to any service, application or API from any device. Our Intelligent Identity Platform can leverage AI and ML to analyze device, network, application and user behavior data to make real-time authentication and security control decisions, enhancing the user experience. Our platform is designed to detect anomalies and automatically insert additional security measures, such as multi-factor authentication, only when necessary. We built our platform to meet the requirements of the most demanding enterprises. Our platform can be deployed across cloud, hybrid and on-premise infrastructures, offers a comprehensive suite of turnkey integrations and is able to scale to millions of identities and thousands of cloud and on-premise applications in a single deployment. As of June 30, 2019, our platform secures over two billion identities globally across our customer base.",PREPACKAGED SOFTWARE,897,2016,,"1001 17th Street, Suite 100, Denver, CO 80202, US",(303) 468-2900,http://www.pingidentity.com,Ping Identity Holding,,$1164.6mil,$215.0 mil (last 12 months),$-10.8 mil (last 12 months),,PING,NYSE,12.5,$15.00 - $15.00,$187.5 mil,Goldman Sachs/ BofA Merrill Lynch/ RBC Capital Markets/ Citigroup,Barclays/ Credit Suisse/ Deutsche Bank Securities/ Wells Fargo Securities/ Raymond James/ Stifel/ William Blair/ Mizuho Securities/ Oppenheimer,9/19/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
3,,"Envista is one of the largest global dental products companies with significant market positions in some of the most attractive segments of the dental products industry, including implants, orthodontics and digital imaging technologies. We develop, manufacture and market one of the most comprehensive portfolios of dental consumables, equipment and services to dental professionals covering an estimated 90% of dentists’ clinical needs for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. Our operating companies, Nobel Biocare Systems, Ormco and KaVo Kerr, serve more than 1 million dentists in over 150 countries through one of the largest commercial organizations in the dental products industry and through our dealer partners. Innovation is a core part of our strategy and we believe that in 2018, our research and development expenditure of $172 million was one of the highest R&D spends in the dental products industry. Our business is deeply rooted in the Danaher operating culture, with an executive officer team that has over 50 collective years of service with Danaher leading a team of over 12,000 employees. In 2018, we generated total sales of $2,845 million, of which approximately 70% were derived from sales of consumables, services and spare parts.",DENTAL EQUIPMENT & SUPPLIES,12800,2018,,"200 S. Kraemer Blvd., Building E, Brea, CA 92821, US",(714) 817-7000,http://www.envistaco.com,Envista Holdings,,$6215.1mil,$2810.3 mil (last 12 months),$214.7 mil (last 12 months),,NVST,NYSE,26.8,$22.00 - $22.00,$588.9 mil,J.P. Morgan/ Goldman Sachs/ Morgan Stanley,Baird/ Evercore ISI/ Jefferies/ BofA Merrill Lynch/ Credit Suisse/ Stifel/ William Blair,9/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
4,,"We are a biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer patients. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to cancer cells than comparable IgG antibodies. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines.",PHARMACEUTICAL PREPARATIONS,51,1993,,"325 E. Middlefield Road, Mountain View, CA 94043, US",(650) 965-7873,http://www.igmbio.com,IGM Biosciences,,$462.3mil,$0 mil (last 12 months),$-33.7 mil (last 12 months),,IGMS,NASDAQ,10.9,$16.00 - $16.00,$175.0 mil,Jefferies/ Piper Jaffray/ Stifel/ Guggenheim Securities,-,9/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
5,,"(Note: A public offering: Prior to this offering, shares of our common stock were quoted on the OTC Markets Group, Inc. OTCQX Marketplace under the symbol “ALRS.”) We are a diversified financial services company headquartered in Grand Forks, North Dakota. Through our subsidiary, Alerus Financial, National Association, we provide innovative and comprehensive financial solutions to businesses and consumers through four distinct business lines—banking, retirement and benefit services, wealth management and mortgage. These solutions are delivered through a relationship-oriented primary point of contact along with responsive and client-friendly technology.",NATIONAL COMMERCIAL BANKS,792,1879,,"401 Demers Avenue, Grand Forks, ND 58201, US",(701) 795-3200,http://www.alerus.com,Alerus Financial,,$350.2mil,$75.6 mil (last 12 months),$28.2 mil (last 12 months),,ALRS,NASDAQ,2.9,$21.00 - $21.00,$60.1 mil,RAYMOND JAMES/ D.A. Davidson & Co.,Piper Jaffray,9/13/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
6,,"We have built a global cloud platform that delivers a broad range of network services to businesses of all sizes and in all geographies—making them more secure, enhancing the performance of their business-critical applications, and eliminating the cost and complexity of managing individual network hardware. Our platform serves as a scalable, easy-to-use, unified control plane to deliver security, performance, and reliability across on-premise, hybrid, cloud, and software-as-a-service (SaaS) applications. Today, approximately 10% of the Fortune 1,000 are paying Cloudflare customers. Additionally, across the broader Internet, approximately 10% of the top million, 17% of the top 100,000, and 18% of the top 10,000 websites use at least one product on our platform on a paid or free basis.",REPACKAGED SOFTWARE,1069,2009,,"101 Townsend Street, San Francisco, CA 94107, US",(888) 993-5273,http://www.cloudflare.com,Cloudflare,,$3813.5mil,$234.7 mil (last 12 months),$-91.5 mil (last 12 months),,NET,NYSE,35.0,$15.00 - $15.00,$525.0 mil,Goldman Sachs/ Morgan Stanley/ J.P. Morgan,Jefferies/ Wells Fargo Securities/ RBC Capital Markets/ JMP Securities/ Evercore ISI/ Needham & Company/ Oppenheimer/ BTIG/ SunTrust Robinson Humphrey,9/13/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
7,,"We are a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine. Our product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the advantages of DHE while overcoming these shortcomings.",PHARMACEUTICAL PREPARATIONS,11,2016,,"400 Oyster Point Boulevard, Suite 221, South San Francisco, CA 94080, US",(650) 410-3200,http://www.satsumarx.com,Satsuma Pharmaceuticals,,$249.1mil,$0 mil (last 12 months),$-13.0 mil (last 12 months),,STSA,NASDAQ,5.5,$15.00 - $15.00,$82.5 mil,Credit Suisse/ SVB Leerink/ Evercore,-,9/13/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
8,,"We are a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. We have a differentiated portfolio of small molecule targeted oncology product candidates and are advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),52,2017,,"100 Washington Blvd., Stamford, CT 06902, US",(203) 883-9490,http://www.springworkstx.com,SpringWorks Therapeutics,,$753.9mil,$0 mil (last 12 months),$-36.5 mil (last 12 months),,SWTX,NASDAQ,9.0,$18.00 - $18.00,$162.0 mil,​J.P. Morgan/ Goldman Sachs/ Cowen​ ​,Wedbush PacGrow,9/13/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
9,,"We are a life science technology company building products to interrogate, understand and master biology. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale.",LABORATORY ANALYTICAL INSTRUMENTS,500,2012,,"6230 Stoneridge Mall Road, Pleasanton, CA 94588, US",(925) 401-7300,https://www.10xgenomics.com,10x Genomics,,$3660.1mil,$196.6 mil (last 12 months),$-105.4 mil (last 12 months),,TXG,NASDAQ,10.0,$39.00 - $39.00,$390.0 mil,J.P. Morgan/ Goldman Sachs/ BofA Merrill Lynch,Cowen,9/12/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
10,,"We are the industry pioneer as the first direct-to-consumer medtech platform for transforming smiles. Through our cutting-edge teledentistry technology and vertically integrated model, we are revolutionizing the oral care industry. Our clear aligner treatment addresses the large and underserved global orthodontics market. An estimated 85% of people worldwide suffer from malocclusion, yet less than 1% receive treatment annually. Our goal is to improve penetration into this untapped market by democratizing access to a more affordable, convenient, and accessible solution for a straighter smile. We believe we are the leading player in this early but massive opportunity. We believe that our aligner treatment can help over 90% of people with malocclusion, to some extent, to achieve a better smile.",DENTAL EQUIPMENT & SUPPLIES,5000,2014,,"414 Union Street, Nashville, TN 37219, US",(800) 848-7566,http://www.SmileDirectClub.com,SmileDirectClub,,$8851.8mil,$621.7 mil (last 12 months),$-93.9 mil (last 12 months),,SDC,NASDAQ,58.5,$23.00 - $23.00,$1346.4 mil,J.P. Morgan/ Citigroup/ BofA Merrill Lynch/ Jefferies/ UBS Investment Bank/ Credit Suisse,Guggenheim Securities/ Stifel/ William Blair/ Loop Capital Markets,9/12/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
11,,"We are a leading digital financial account platform integrating and personalizing financial services in China with our footprint expanding overseas. We provide a comprehensive range of financial products and services across loan products, online wealth management products, and payment facilitation, all integrated under a single digital financial account. According to Oliver Wyman, among the independent marketplace lending platforms in China, we are the largest online consumer finance platform in terms of outstanding loan balance as of December 31, 2018. We leverage technology, a deep understanding of our large user base and strategic partner relationships to create a one-stop experience bringing together borrowers, investors, financial institution partners and merchant partners.",FINANCE SERVICES,1516,2006,,"Jiufu Building, Rongxin Technology Center, Chaoyang District, Beijing, People's Republic of China, 100102",+86 (10) 8527-6996,http://www.9fgroup.com,9F,,$1841.6mil,$824.7 mil (last 12 months),$320.2 mil (last 12 months),,JFU,NYSE,8.9,$9.50 - $9.50,$84.6 mil,Credit Suisse,Haitong International/ 9F Primasia Securities,8/15/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
12,,"We are a leading global provider of innovative, energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. Within the global aesthetics market, our products and solutions are primarily designed to address three energy-based treatment categories comprised of: (i) face and body contouring; (ii) medical aesthetics; and (iii) women’s health. We have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling.",ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS,209,2008,,"Tavor Building, Sha’ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel",+972-4-9096313,http://www.inmodemd.com,InMode Ltd.,,$447.6mil,$109.8 mil (last 12 months),$26.1 mil (last 12 months),,INMD,NASDAQ,5.0,$14.00 - $14.00,$70.0 mil,​Barclays/ UBS Investment Bank/ Canaccord Genuity,Baird,8/8/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
13,,"We are a leading Hong Kong-headquartered comprehensive financial institution. We are one of the few financial institutions with extensive financial industry knowledge and experience across Greater China that is majority-owned and managed by local Hong Kong entrepreneurs and professionals. This genuine “Hong Kong-owned” identity positions us to play an instrumental role in connecting local clients from Hong Kong and China with global capital markets. Compared to other global and Chinese market players in Hong Kong, we believe that we benefit from greater execution efficiency, supreme local market and industry know-how, and unparalleled access to the sizeable capital of Asia’s tycoon families. Our global capital markets expertise, coupled with deep roots in Asia, have propelled us to become one of the “go-to” financial institutions in Hong Kong, fulfilling the complex financial needs of our clients across all phases of their growth and development. Our clientele includes PRC banks, privately-owned companies primarily in new economy sectors, and Hong Kong-based blue-chip conglomerates, among others.",FINANCIAL SERVICES,31,2003,,"23/F Nexxus Building, 41 Connaught Road Central, Hong Kong",+852 3163-3389,http://www.amtdinc.com,AMTD International,,$1933.0mil,$155.5 mil (last 12 months),$116.9 mil (last 12 months),,HKIB,NYSE,20.8,$8.38 - $8.38,$174.0 mil,AMTD Global Markets,Loop Capital Markets/ MasterLink/ Tiger Brokers/ ViewTrade Securities,8/5/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
14,,"We offer the market-leading software intelligence platform, purpose-built for the enterprise cloud. As enterprises embrace the cloud to effect their digital transformation, our all-in-one intelligence platform is designed to address the growing complexity faced by technology and digital business teams. Our platform utilizes artificial intelligence at its core and advanced automation to provide answers, not just data, about the performance of applications, the underlying hybrid cloud infrastructure, and the experience of our customers’ users. We designed our software intelligence platform to allow our customers to modernize and automate IT operations, develop and release high quality software faster, and improve user experiences for better business outcomes.",PREPACKAGED SOFTWARE,1981,2014,,"1601 Trapelo Road, Suite 116 Waltham, MA 02451, US",(781) 530-1000,http://www.dynatrace.com,Dynatrace Holdings,,$4408.6mil,$460.96 mil (last 12 months),$-116.2 mil (last 12 months),,DT,NYSE,35.6,$16.00 - $16.00,$569.8 mil,Goldman Sachs/ J.P. Morgan/ Citigroup,Barclays/ Jefferies/ RBC Capital Markets/ UBS Investment Bank/ KeyBanc Capital Markets/ William Blair/ Canaccord Genuity/ JMP Securities/ Macquarie Capital,8/1/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
15,,"Sundial’s mission is to proudly craft pioneering cannabis brands to Heal, Help and Play. We view these as three distinct consumer opportunities, defined as follows: Heal— cannabis products used as prescription medicine Help— cannabis products that strive to promote overall health and wellness through CBD Play— cannabis products to enhance social, spiritual and recreational occasions",MEDICINAL CHEMICALS & BOTANICAL PRODUCTS,937,2006,,"#200, 919 – 11 Avenue SW, Calgary, Alberta, Canada T2R 1P3",(403) 948-5227,http://www.sundialcannabis.com,Sundial Growers,,$1089.5mil,$10.8 mil (last 12 months),$-22.8 mil (last 12 months),,SNDL,NASDAQ,11.0,$13.00 - $13.00,$143.0 mil,Cowen/ BMO Capital Markets/ Barclays,-,8/1/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
16,,"We are a producer, developer and operator of augmented reality (AR) interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile game features. Our mobile-connected entertainment platform enables us to connect physical items to mobile devices through wireless technologies, creating a unique interactive user experience. Our goal is to create a rich visual and interactive environment for users through the integration of real objects and virtual scenery. We believe this combination provides users with a more natural form of human-computer interaction and enhances users’ perception of reality, thus providing a more diversified entertainment experience. By leveraging our strong technological capabilities and infrastructure, we are able to deliver a superior user experience and conduct our operations in a highly efficient manner.","GAMES, TOYS & CHILDREN'S VEHICLES (NO DOLLS & BICYCLES)",107,2010,,"7th Floor, Building C, No. 1010 Anling Road, Huli District, Xiamen, China 361009",86-592-228-0081,http://www.bluehatgroup.net,Blue Hat Interactive Entertainment Technology,,$150.0mil,$18.5 mil (last 12 months),$7.9 mil (last 12 months),,BHAT,NASDAQ,2.0,$4.00 - $4.00,$8.0 mil,ViewTrade Securities,-,7/26/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
17,,"We are a global sports events, media and marketing platform with significant intellectual property rights, long-term relationships and broad execution capabilities through which we create value for stakeholders in all parts of the sports ecosystem, from rights owners, to brands and advertisers and to fans and athletes. We own, or otherwise have contractual rights to, an extensive portfolio of global, regional and national sports properties from which we seek to generate revenue across the value chain, including events operation, media production and media distribution, sponsorship and marketing, digital solutions and ancillary services. We have combined the strengths of our Infront, WEH and WSC businesses to form one of the world’s largest sports events, media and marketing platforms in terms of revenue in 2018 (unless otherwise indicated, statements as to markets, including our leading positions in such markets, in this section are derived from an industry report commissioned by us and prepared by Frost & Sullivan, a third-party research firm; see “Industry Overview” for further information).",AMUSEMENT & RECREATION SERVICES,1624,2018,,"9/F, Tower B, Wanda Plaza, 93 Jianguo Road, Chaoyang District, 100022, Beijing, PRC",+86-10-8585-3450,http://www.wsg.cn,Wanda Sports Group,,$1640mil,$1292.7 mil (last 12 months),$47.1 mil (last 12 months),,WSG,NASDAQ,23.8,$8.00 - $8.00,$190.4 mil,Morgan Stanley/ Deutsche Bank Securities/ Citigroup,Haitong International/ CICC/ CLSA,7/26/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
18,,"We are a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. We believe that the traditional approach to developing a treatment plan for certain cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information.",MEDICAL LABORATORIES,96,2007,,"820 S. Friendswood Drive, Suite 201, Friendswood, TX 77546, US",(866) 788-9007,http://www.CastleBiosciences.com,Castle Biosciences,,$256.8mil,$27.8 mil (last 12 months),$-8.0 mil (last 12 months),,CSTL,NASDAQ,4.0,$16.00 - $16.00,$64.0 mil,SVB Leerink/ Baird,Canaccord Genuity/ BTIG,7/25/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
19,,"We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Our customers, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. We envision a future where all healthcare decisions are data informed.","COMPUTER PROGRAMMING, DATA PROCESSING",700,2011,,"3165 Millrock Drive #400, Salt Lake City, UT 84121, US",(801) 708-6800,http://www.healthcatalyst.com,Health Catalyst,,$859.4mil,$127.2 mil (last 12 months),$-190.0 mil (last 12 months),,HCAT,NASDAQ,7.0,$26.00 - $26.00,$182.0 mil,Goldman Sachs/ J.P. Morgan/ William Blair,Piper Jaffray/ Evercore ISI/ SVB Leerink/ SunTrust Robinson Humphrey,7/25/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
20,,"Our mission is to empower people with chronic conditions to live better and healthier lives. The advancement of technology and data science has transformed nearly every industry except healthcare to create new, consumer-first experiences that are both personalized and empowering. Livongo is pioneering a new category in healthcare, called Applied Health Signals, which is transforming the management of chronic conditions.",MISC HEALTH & ALLIED SERVICES,471,2008,,"150 West Evelyn Avenue, Mountain View, California 94041, US",(866) 435-5643,http://www.livongo.com,Livongo Health,,$2545.8mil,$88.0 mil (last 12 months),$-44.3 mil (last 12 months),,LVGO,NASDAQ,12.7,$28.00 - $28.00,$355.2 mil,Morgan Stanley/ Goldman Sachs/ J.P. Morgan,Piper Jaffray/ SVB Leerink/ Canaccord Genuity/ KeyBanc Capital Markets/ Needham & Company,7/25/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
21,,"We are an entrepreneurial specialty insurance company that since our founding in 2009 has built products, services and solutions with the goal of significantly improving the experience and value proposition for our customers. In our view, property and casualty insurance companies and the independent agents who typically distribute their products have operated under a model where carriers have little direct connectivity to their customers and as a result, often have a limited ability and incentive to understand and service customers’ needs, or to innovate and adapt as those insurance needs change.","FIRE, MARINE & CASUALTY INSURANCE",392,2010,,"412 Mt. Kemble Avenue, Suite 300, Morristown, NJ 07960, US",(973) 532-1900,http://www.prosightspecialty.com,ProSight Global,,$601.99mil,$901.5 mil (last 12 months),$58.6 mil (last 12 months),,PROS,NYSE,7.9,$14.00 - $14.00,$110.0 mil,Goldman Sachs/ Barclays/ BofA Merrill Lynch,"Dowling & Partners/ Keefe, Bruyette & Woods (A Stifel Company)/ SunTrust Robinson Humphrey/ Citizens Capital Markets",7/25/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
22,,"We are a leading residential solar and energy storage service provider, serving more than 63,000 customers in more than 20 U.S. states and territories. Our goal is to be a leading provider of clean, affordable, and reliable energy for consumers, and we operate with a simple mission: to power energy independence. We were founded to deliver customers a better energy service at a better price, and through our solar and solar plus energy storage service offerings we are disrupting the traditional energy landscape and the way the 21st century customer generates and consumes electricity.",ELECTRIC & OTHER SERVICES COMBINED,299,2012,,"20 East Greenway Plaza, Suite 475, Houston, TX 77046, US",(281) 985-9904,http://www.sunnova.com,Sunnova Energy International,,$1084.5mil,$111.3 mil (last 12 months),$-98.6 mil (last 12 months),,NOVA,NYSE,14.0,$12.00 - $12.00,$168.0 mil,BofA Merrill Lynch/ J.P. Morgan/ Goldman Sachs/ Credit Suisse,KeyBanc Capital Markets/ Baird/ Roth Capital Partners,7/25/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
23,,"We are the leading medical education group in Brazil based on number of medical school seats, as published by MEC as of December 31, 2018, delivering an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners from the moment they join us as medical students through their medical residency preparation, graduation program, and CME. Our innovative methodological approach combines integrated content, interactive learning, and an adaptive experience for lifelong medical learners. Through our educational content and technology-enabled activities, we focus on effective, personalized learning that mirrors one-on-one tutoring. We have the largest medical education footprint in Brazil. Our undergraduate and graduate campuses are spread across 12 Brazilian states, and our digital medical platform is available across Brazil. As of March 31, 2019 and as of December 31, 2018, our network of 14 undergraduate and graduate medical school campuses consisted of 9 operating units (units that have been approved by MEC and that have commenced operations) and 5 approved units (units that have been approved by MEC but that have not yet commenced operations), compared to 4 operating units as of March 31, 2018 and as of December 31, 2017. As of March 31, 2019 and as of December 31, 2018, our network of 1,167 medical school seats consisted of 917 operating seats (seats that have been approved by MEC and that have commenced operations) and 250 approved seats (seats that have been approved by MEC but that have not yet commenced operations), compared to 636 and 420 operating seats as of March 31, 2018 and as of December 31, 2017, respectively.",EDUCATIONAL SERVICES,2705,1999,,"Alameda Oscar Niemeyer, No. 119, Sala 504, Vila da Serra, Nova Lima, Minas Gerais, Brazil",+55 (31) 3515 7500,http://www.afya.com.br,Afya Limited,,$565.3mil,$109.7 mil (last 12 months),$32.95 mil (last 12 months),,AFYA,NYSE,13.7,$19.00 - $19.00,$261.1 mil,BofA Merrill Lynch/ Goldman Sachs/ UBS Investment Bank/ Itaú BBA/Morgan Stanley/ BTG/ Pactual XP Investments,-,7/19/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
24,,"We created a new category of enterprise software, experience management, and we are the market leader. Our award-winning SaaS platform, the Medallia Experience Cloud, captures experience data from massive and expanding signal fields emitted by customers and employees on their daily journeys and is a leader in the market for understanding and managing omni-channel experiences. We utilize our proprietary AI technology to analyze structured and unstructured data from these signal fields across human, digital and IoT interactions at great scale to derive personalized and predictive insights that drive action with tremendous business results.","COMPUTER PROGRAMMING, DATA PROCESSING",1258,2000,,"575 Market Street, Suite 1850, San Francisco, CA 94105, US",(650) 321-3000,http://www.medallia.com,Medallia,,$2587.7mil,$336.6 mil (last 12 months),$-57.3 mil (last 12 months),,MDLA,NYSE,15.5,$21.00 - $21.00,$325.5 mil,BofA Merrill Lynch/ Citigroup/ Wells Fargo Securities/ Credit Suisse,Oppenheimer/ SunTrust Robinson Humphrey/ William Blair/ Needham & Company/ Craig-Hallum Capital Group/ Roth Capital Partners,7/19/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
25,,"We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. We have developed a proprietary product engine that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat the known root cause of genetically defined diseases. We are using our product engine to identify targets that can be drugged by small molecules regardless of the particular underlying mechanism of gene mis-expression.",PHARMACEUTICAL PREPARATIONS,62,2015,,"26 Landsdowne Street, Cambridge, MA 02139, US",(617) 651-8851,http://www.fulcrumtx.com,Fulcrum Therapeutics,,$373.4mil,$0 mil (last 12 months),$-71.3 mil (last 12 months),,FULC,NASDAQ,4.5,$16.00 - $16.00,$72.0 mil,Morgan Stanley/ BofA Merrill Lynch/ SVB Leerink,-,7/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
26,,"We are a specialty finance company focused on lending to U.S. middle-market companies. We invest in senior secured or unsecured loans, subordinated loans or mezzanine loans and, to a lesser extent, equity-related securities including warrants, preferred stock and similar forms of senior equity, which may or may not be convertible into a portfolio company’s common equity. The debt in which we invest typically is not rated by any rating agency, but if these instruments were rated, they would likely receive a rating of below investment grade (that is, below BBB- or Baa3), which is often referred to as “high yield” or “junk”. Our investment objective is to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns.",FINANCE SERVICES,0,2015,,"399 Park Avenue, 38th Floor New York, NY 10022, US",(212) 419-3000,http://www.owlrock.com,Owl Rock Capital,,,$474.8 mil (last 12 months),$272.4 mil (last 12 months),,ORCC,NYSE,0.0,$0.00 - $0.00,$172.5 mil,"Goldman Sachs/ BofA Merrill Lynch/ RBC Capital Markets/ SunTrust Robinson Humphrey/ Wells Fargo Securities/ Credit Suisse/ Deutsche Bank Securities/ JMP Securities/ Keefe, Bruyette & Woods (A Stifel Company)/ Morgan Stanley/ SOCIETE GENERALE",ING/ Janney Montgomery Scott/ Ladenburg Thalmann/ MUFG,,TBA,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
27,,"We are a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. As evidenced in industry survey reports from KLAS, we have been recognized as a leader based on our integration capabilities with healthcare provider organizations, the broad adoption of our patient intake functionalities and by overall client satisfaction. Through the SaaS-based Phreesia Platform (the “Phreesia Platform” or “our Platform”), we offer healthcare provider organizations (our “provider clients”) a robust suite of solutions to manage the patient intake process and an integrated payments solution for secure processing of patient payments.",BUSINESS SERVICES,436,2005,,"432 Park Avenue South, 12th Floor , New York, NY 10016, US",(888) 654-7473,http://www.phreesia.com,Phreesia,,$639.1mil,$104.3 mil (last 12 months),$-54.1 mil (last 12 months),,PHR,NYSE,9.3,$18.00 - $18.00,$167.2 mil,J.P. Morgan/ Wells Fargo Securities/ William Blair/ Allen & Company/ Piper Jaffray,-,7/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
28,,"We are the largest game-centric live streaming platform in China and a pioneer in the eSports value chain. We operate our platform both on PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. According to iResearch, among China’s game-centric live streaming platforms, we ranked: • first by the size of our user base as measured by average total MAUs on both mobile and PC platforms during the fourth quarter of 2017 and 2018; • first by the level of user engagement as measured by average total daily time spent by active users on our platform during the fourth quarter of 2017 and 2018; and • first by the number of top 100 game streamers with whom we contracted in December 2017 and December 2018.","COMPUTER PROGRAMMING, DATA PROCESSING, ETC.",2080,2014,,"Building F4, Optical Valley Software Park, Guanshan Avenue, Donghu Development Area, Wuhan, the People's Republic of China",+86 27 8775 0710,http://www.douyu.com,DouYu International Holdings,,$4138.9mil,$650.7 mil (last 12 months),$-90.7 mil (last 12 months),,DOYU,NASDAQ,67.4,$11.50 - $11.50,$775.0 mil,Morgan Stanley/ J.P. Morgan/ BofA Merrill Lynch/ CMBI,-,7/17/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
29,,"We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Our pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. We are currently conducting a Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and expect topline results in late 2019.",PHARMACEUTICAL PREPARATIONS,16,2009,,"33 Arch Street, Suite 3110, Boston, MA 02110, US",(857) 449-2244,http://www.karunatx.com,Karuna Therapeutics,,$341.9mil,$0 mil (last 12 months),$-27.1 mil (last 12 months),,KRTX,NASDAQ,5.6,$16.00 - $16.00,$89.2 mil,Goldman Sachs/ Citigroup/ Wells Fargo Securities,Wedbush PacGrow,6/28/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
30,,"We are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),346,2009,,"1551 Eastlake Avenue East, Suite 200, Seattle, Washington 98102, US",(206) 659-0067,http://www.adaptivebiotech.com,Adaptive Biotechnologies,,$2419.5mil,$58.6 mil (last 12 months),$-52.6 mil (last 12 months),,ADPT,NASDAQ,15.0,$20.00 - $20.00,$300.0 mil,Goldman Sachs/ J.P. Morgan/ BofA Merrill Lynch,Cowen/ Guggenheim Securities/ William Blair/ BTIG,6/27/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
31,,"We are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. We founded BridgeBio in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Our pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development.",PHARMACEUTICAL PREPARATIONS,152,2015,,"421 Kipling Street, Palo Alto, CA 94301, US",(650) 391-9740,http://www.bridgebio.com,BridgeBio Pharma,,$2048.5mil,$0 mil (last 12 months),$-167.9 mil (last 12 months),,BBIO,NASDAQ,20.5,$17.00 - $17.00,$348.5 mil,J.P. Morgan/ Goldman Sachs/ Jefferies/ SVB Leerink/ KKR,Piper Jaffray/ Mizuho Securities/ BMO Capital Markets/ Raymond James,6/27/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
32,,"We are a leading independent healthcare technology platform that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system. We offer a comprehensive suite of software, analytics, technology-enabled services and network solutions that drive improved results in the complex workflows of healthcare system payers and providers. Our solutions are designed to improve clinical decision making, simplify billing, collection and payment processes and enable a better patient experience.",COMPUTER PROCESSING & DATA PREPARATION,14000,2016,,"3055 Lebanon Pike, Suite 1000, Nashville, TN 37214, US",615-932-3000,https://www.changehealthcare.com,Change Healthcare,,$3826.2mil,$0 mil (last 12 months),$-51.9 mil (last 12 months),,CHNG,NASDAQ,42.9,$13.00 - $13.00,$557.1 mil,Barclays/ Goldman Sachs/ J.P. Morgan/ BofA Merrill Lynch/ Citigroup/ Credit Suisse/ Deutsche Bank Securities/ Morgan Stanley/ RBC Capital Markets,Blackstone Capital Markets/ Baird/ Cantor/ Cowen/ First Liberties Financial/ Guggenheim Securities/ Piper Jaffray/ SunTrust Robinson Humphrey/ SVB Leerink/ Wells Fargo Securities / William Blair/ Drexel Hamilton/ Siebert Cisneros Shank & Co.,6/27/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
33,,"We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small-molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite significant unsuccessful efforts, we believe tremendous untapped potential remains for us to develop oral integrin therapies.",PHARMACEUTICAL PREPARATIONS,65,2014,,"35 Gatehouse Drive, A2, Waltham, MA 02451, US",(781) 996-0955,http://www.morphictx.com,Morphic Holding,,$443.9mil,$9.4 mil (last 12 months),$-23.9 mil (last 12 months),,MORF,NASDAQ,6.0,$15.00 - $15.00,$90.0 mil,Jefferies/ Cowen/ BMO Capital Markets/ Wells Fargo Securities,-,6/27/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
34,,"The Trust has adopted restrictions and policies relating to the investment of the Trust’s assets and its activities. Certain of the restrictions are fundamental policies of the Trust and may not be changed without the approval of the holders of a majority of the Trust’s outstanding voting securities (which for this purpose and under the Investment Company Act means the lesser of (i) 67% of the shares represented at a meeting at which more than 50% of the outstanding shares are represented or (ii) more than 50% of the outstanding shares), including class approval by a majority of the Trust’s outstanding preferred shares, if any (which for this purpose and under the Investment Company Act means the lesser of (i) 67% of the preferred shares, as a single class, represented at a meeting at which more than 50% of the Trust’s outstanding preferred shares are represented or (ii) more than 50% of the outstanding preferred shares).",FINANCIAL SERVICES,,2019,,"100 Bellevue Parkway, Wilmington, DE 19809, US",(800) 882-0052,http://www.blackrock.com,BlackRock Science and Technology Trust II,,$1400.0mil,$0 mil (last 12 months),$0 mil (last 12 months),,BSTZ,NYSE,70.0,$20.00 - $20.00,$1400.0 mil,Morgan Stanley/ BofA Merrill Lynch/ UBS Investment Bank/ Wells Fargo Securities/ Raymond James,Ameriprise Financial Services/ Oppenheimer/ RBC Capital Markets/ Stifel/ B. Riley Wealth Management/ BB&T Capital Markets/ Brookline Capital Markets/ Incapital/ Janney Montgomery Scott/ JonesTrading/ Ladenburg Thalmann/ Maxim Group/ Newbridge Securities Corporation/ Pershing,6/26/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
35,,"We provide wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises and government agencies. Our scalable, reliable and high performance solutions create a purpose built wireless fabric which connects people, places and things across distances ranging from two meters to more than 100 kilometers, indoors and outdoors, using licensed and unlicensed spectrum, at attractive economics.",RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT,516,2011,,"3800 Golf Road, Suite 360, Rolling Meadows, Illinois 60008, US",(888) 863-5250,http://www.cambiumnetworks.com,Cambium Networks,,$307.3mil,$251.4 mil (last 12 months),$0.58 mil (last 12 months),,CMBM,NASDAQ,5.8,$12.00 - $12.00,$69.6 mil,J.P. Morgan/ Goldman Sachs,Deutsche Bank Securities/ Raymond James/ JMP Securities/ Oppenheimer,6/26/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
36,,"We are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Our initial focus is on nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. NASH is a leading cause for liver transplantation.",PHARMACEUTICAL PREPARATIONS,8,2017,,"170 Harbor Way, 3rd Floor, South San Francisco, CA 94080, US",(650)-487-6488,http://www.akerotx.com,Akero Therapeutics,,$432.7mil,$0 mil (last 12 months),$-87.2 mil (last 12 months),,AKRO,NASDAQ,5.8,$16.00 - $16.00,$92.0 mil,J.P. Morgan/ Jefferies/ Evercore ISI,Roth Capital Partners,6/20/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
37,,"We are a biopharmaceutical company utilizing our differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, our approach relies on the human immune system to direct us to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.",PHARMACEUTICAL PREPARATIONS,85,2011,,"500 Saginaw Drive, Redwood City, CA 94063, US",(650) 595-2595,https://www.atreca.com/,Atreca,,$455.3mil,$0 mil (last 12 months),$-43.9 mil (last 12 months),,BCEL,NASDAQ,7.4,$17.00 - $17.00,$125.0 mil,Cowen/ Evercore ISI/ Stifel,Canaccord Genuity/ Brookline Capital Markets,6/20/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
38,,"We are a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. We designed our NeXT Platform to adapt to the complex and evolving understanding of cancer, providing our biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover roughly 50 to 500 genes. We are also developing a complementary liquid biopsy assay that analyzes all human genes versus the more narrowly focused liquid biopsy assays that are currently available.",MEDICAL LABORATORIES,147,2011,,"1330 O’Brien Drive, Menlo Park, CA 94025, US",(650) 752-1300,https://www.personalis.com,Personalis,,$505.8mil,$47.7 mil (last 12 months),$-20.2 mil (last 12 months),,PSNL,NASDAQ,7.9,$17.00 - $17.00,$134.7 mil,Morgan Stanley/ BofA Merrill Lynch/ Cowen,Oppenheimer,6/20/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
39,,"We are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. We are applying a precision medicine approach to neurodegeneration by studying our gene therapies in genetically defined patient populations. We believe this will increase the probability of creating disease-modifying therapies that improve patients’ lives. Our lead program is PR001 for the treatment of Parkinson’s disease with GBA1 mutation, or PD-GBA, and neuronopathic Gaucher disease. We are focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),43,2017,,"430 East 29th Street, Suite 940, New York, New York 10016, US",(917) 336-9310,http://www.prevailtherapeutics.com,Prevail Therapeutics,,$577.9mil,$0 mil (last 12 months),$-25.8 mil (last 12 months),,PRVL,NASDAQ,7.4,$17.00 - $17.00,$125.0 mil,Morgan Stanley/ BofA Merrill Lynch/ Cowen,Wedbush PacGrow,6/20/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
40,,"Our mission is to be the most trusted and convenient online destination for pet parents everywhere. Since our launch, we have created the largest pure-play pet e-tailer in the United States, offering virtually everything a pet needs. We believe that we are the preeminent online destination for pet parents as a result of our broad selection of high-quality products, which we offer at great prices and deliver with an exceptional level of care and a personal touch. We are the trusted source for pet parents and continually develop innovative ways for our customers to engage with us. We partner with more than 1,600 of the best and most trusted brands in the pet industry, and we create and offer our own outstanding private brands.",CATALOG & MAIL-ORDER HOUSES,9833,2011,,"1855 Griffin Road, Suite B-428, Dania Beach, FL 33004, US",(786) 320-7111,http://www.chewy.com,Chewy,,$8769.2mil,$3532.8 mil (last 12 months),$-267.9 mil (last 12 months),,CHWY,NYSE,46.5,$22.00 - $22.00,$1023.0 mil,Morgan Stanley/ J.P. Morgan/ Allen & Company,BofA Merrill Lynch/ Barclays/ Jefferies/ RBC Capital Markets/ UBS Investment Bank/ Wells Fargo Securities/ Nomura/ Raymond James/ William Blair,6/14/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
41,,"Our mission is to change how the world works together. We started with the simple idea that people should be able to buy and sell digital services in the same fashion as physical goods on an e-commerce platform. On that basis, we set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and an efficient search, find and order process that mirrors a typical e-commerce transaction. We believe our model reduces friction and uncertainties for both buyers and sellers. At the foundation of our platform lies an expansive catalog with over 200 categories of productized service listings, which we coined as Gigs. Each Gig has a clearly defined scope, duration and price, along with buyer-generated reviews.",BUSINESS SERVICES,363,2010,,"8 Eliezer Kaplan St., Tel Aviv 6473409, Israel",+972-72-2280910,http://www.fiverr.com,Fiverr International Ltd.,,$650.9mil,$82.5 mil (last 12 months),$-28.1 mil (last 12 months),,FVRR,NYSE,5.3,$21.00 - $21.00,$110.5 mil,J.P. Morgan Securities/ Citigroup,BofA Merrill Lynch/ UBS Securities/ JMP Securities/ Needham & Company/ Oppenheimer/ UBS Securities,6/13/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
42,,"Mohawk is a rapidly growing technology-enabled consumer products company. Mohawk was founded on the premise that if a CPG company was founded today, it would apply A.I. and machine learning, the synthesis of massive quantities of data and the use of social proof to validate high caliber product offerings as opposed to over-reliance on brand value and other traditional marketing tactics.",ELECTRIC HOUSEWARES & FANS,142,2014,,"37 East 18th Street, 7th Floor, New York, NY 10003, US",(347) 676-1681,http://www.mohawkgp.com,Mohawk Group Holdings,,$175.4mil,$76.8 mil (last 12 months),$-31.0 mil (last 12 months),,MWK,NASDAQ,3.6,$10.00 - $10.00,$36.0 mil,Roth Capital Partners/ A.G.P.,National Securities Corporation,6/12/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
43,,"We are a technology-driven education company. Our core expertise is in online K-12 courses, and we are the third largest online K-12 large-class after-school tutoring service provider in China in terms of gross billings in 2018, according to Frost & Sullivan. Our K-12 courses cover all primary and secondary grades, and contributed over 73% and 75% of our total revenues in 2018 and for the three months ended March 31, 2019, respectively. We also offer foreign language, professional and interest courses.",EDUCATIONAL SERVICES,1746,2014,,"Tower C, Beyondsoft Building, 7 East Zone, 10 Xibeiwang East Road, Haidian District, Beijing 100193, People’s Republic of China",+86 10 8282-6826,http://www.baijiahulian.com,GSX Techedu,,$1644.8mil,$91.4 mil (last 12 months),$1.7 mil (last 12 months),,GSX,NYSE,19.8,$10.50 - $10.50,$207.9 mil,Credit Suisse/ Deutsche Bank Securities,Barclays/ CLSA,6/6/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
44,,"We are a clinical-stage biopharmaceutical company developing a novel class of medicines, which we refer to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic, or PK, properties of a small molecule. Bicycles are excreted by the kidney rather than the liver and have shown no signs of immunogenicity to date, which we believe together support a favorable toxicological profile.",PHARMACEUTICAL PREPARATIONS,61,2009,,"B900, Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom",+44 1223 261503.,http://www.bicycletherapeutics.com,Bicycle Therapeutics Limited,,$247.7mil,$7.1 mil (last 12 months),$-21.8 mil (last 12 months),,BCYC,NASDAQ,4.3,$14.00 - $14.00,$60.7 mil,Goldman Sachs/ Jefferies/ Piper Jaffray,Canaccord Genuity,5/23/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
45,,"We are an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.",PHARMACEUTICAL PREPARATIONS,58,2015,,"7000 Shoreline Court, Suite 350, South San Francisco, CA 94080, US",(650) 443-6209,http://www.ideayabio.com,IDEAYA Biosciences,,$194.8mil,$0 mil (last 12 months),$-38.1 mil (last 12 months),,IDYA,NASDAQ,5.0,$10.00 - $10.00,$50.0 mil,J.P. Morgan/ Citigroup/ Jefferies,-,5/23/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
46,,"We are a growth-oriented Delaware limited partnership formed by Diamondback in July 2018 to own, operate, develop and acquire midstream infrastructure assets in the Midland and Delaware Basins of the Permian, one of the most prolific oil producing areas in the world. Immediately following this offering, we expect to be the only publicly-traded, pure-play Permian midstream operator. We provide crude oil, natural gas and water-related midstream services (including fresh water sourcing and transportation and saltwater gathering and disposal) to Diamondback under long-term, fixed-fee contracts. The assets Diamondback has contributed to us include 528 miles of pipeline across the Midland and Delaware Basins with approximately 216,000 Bbl/d of crude oil gathering capacity, 589,000 Bbl/d of SWD capacity, 740,700 Bbl/d of fresh water gathering capacity, 36,000 Mcf/d of natural gas compression capability and 150,000 Mcf/d of natural gas gathering capacity. In addition to the midstream infrastructure assets that Diamondback contributed to us, we also have an option, subject to certain conditions, to acquire equity in a long-haul crude oil pipeline, which will run from the Permian to the Texas Gulf Coast.",NATURAL GAS TRANSMISSION,676,2007,,"500 West Texas, Suite 1200, Midland, TX 79701, US",(432) 221-7400.,http://www.rattlermidstream.com,Rattler Midstream Partners LP,,$2651.3mil,$245.8 mil (last 12 months),$87.9 mil (last 12 months),,RTLR,NASDAQ,38.0,$17.50 - $17.50,$665.0 mil,Credit Suisse/ BofA Merrill Lynch/ J.P. Morgan/ Barclays/ Citigroup/ Goldman Sachs/ Wells Fargo Securities,"Capital One Securities/ Scotia Howard Weil/ SunTrust Robinson Humphrey/ UBS Investment Bank/ Evercore ISI/ Morgan Stanley/ RBC Capital Markets/ Simmons Energy (A Division of Piper Jaffray)/ Tudor, Pickering, Holt/ Raymond James/ Seaport Global Securities/ Northland Capital Markets/ PNC Capital Markets/ TD Securities",5/23/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
47,,"We are a leading global provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our comprehensive offerings, which include materials & consumables, equipment & instrumentation and services & specialty procurement, are relied upon by our customers, often on a recurring basis, because they are frequently specified into their research, development and production processes. These processes are commonly organized into “workflows” that define the activities our customers perform each day.",LABORATORY ANALYTICAL INSTRUMENTS,12000,1904,,"Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road, Radnor, PA 19087, US",(610) 386-1700,http://www.avantorinc.com,Avantor,,$7480.1mil,$5926.1 mil (last 12 months),$-51.9 mil (last 12 months),,AVTR,NYSE,207.0,$14.00 - $14.00,$2898.0 mil,Goldman Sachs/ J.P. Morgan/ BofA Merrill Lynch/ Barclays/ Jefferies,Credit Suisse/ Deutsche Bank Securities/ Evercore ISI/ Guggenheim Securities/ Morgan Stanley/ UBS Investment Bank/ Citigroup/ Cowen/ Piper Jaffray/ RBC Capital Markets/ Baird/ William Blair/ Janney Montgomery Scott/ KeyBanc Capital Markets/ PJT Partners/ Raymond James/ Stephens/ Stifel/ SunTrust Robinson Humphrey/ Wells Fargo Securities/ Drexel Hamilton,5/17/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
48,,"Developers are reinventing the way we live, work, and play online. Yet they repeatedly encounter innovation barriers when delivering modern digital experiences. Expectations for digital experiences are at an all-time high; they must be fast, secure, and highly personalized. If they aren’t reliable, end-users simply take their business elsewhere. The challenge today is enabling developers to deliver a modern digital experience while simultaneously providing scale, security, and performance. We built our edge cloud platform to solve this problem.The edge cloud is a new category of IaaS that enables developers to build, secure, and deliver digital experiences, at the edge of the internet.",PREPACKAGED SOFTWARE,489,2011,,"475 Brannan Street, Suite 300, San Francisco, CA 94107, US",1-844-432-7859,http://www.fastly.com,Fastly,,$14510.0mil,$157.6 mil (last 12 months),$-31.4 mil (last 12 months),,FSLY,NYSE,11.3,$16.00 - $16.00,$168.8 mil,BofA Merrill Lynch/ Credit Suisse/ Citigroup,William Blair/ Raymond James/ Baird/ Oppenheimer/ Craig-Hallum Capital Group/ D.A. Davidson & Co.,5/17/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
49,,"We are an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Upon completion of this offering and the related formation transactions, we will own and manage an initial portfolio of 271 postal properties located in 40 states comprising 871,843 net leasable interior square feet, all of which are leased to the USPS, and through our taxable REIT subsidiary, or TRS, we will provide fee-based third party property management services for an additional 401 postal properties leased to the USPS and owned by members of Mr. Spodek’s family and their partners.",REAL ESTATE INVESTMENT TRUSTS,0,2018,,"75 Columbia Avenue, Cedarhurst, NY 11516, US",(516) 295-7820,http://www.postalrealtytrust.com,Postal Realty Trust,,$90.3mil,$7.68 mil (last 12 months),$1.14 mil (last 12 months),,PSTL,NYSE,4.5,$17.00 - $17.00,$76.5 mil,Stifel/ Janney Montgomery Scott/ BMO Capital Markets/ Height Capital Markets,B. Riley FBR/ D.A. Davidson,5/15/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
50,,"We are a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. We focus on molecules and pathways whose role in the disease process is well known based on prior research, but have previously failed to yield successful products due to poor efficacy and tolerability. Our unique approach to drug development leverages recent technological advances to design improved drugs, employs early use of biomarkers to confirm biological activity and focuses on abbreviated regulatory pathways. Our first molecular target is aldose reductase, or AR, an enzyme that converts glucose to sorbitol under oxidative stress conditions, and is implicated in multiple diseases.",PHARMACEUTICAL PREPARATIONS,9,2015,,"340 Madison Avenue, 19th Floor, New York, NY 10173, US",(212) 220-9226,http://www.appliedtherapeutics.com,Applied Therapeutics,,$170.5mil,$0 mil (last 12 months),$-16.5 mil (last 12 months),,APLT,NASDAQ,4.0,$10.00 - $10.00,$40.0 mil,Citigroup/ Cowen/ UBS Investment Bank,Baird,5/13/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
51,,"We are a leading online individual finance marketplace in China connecting individual investors and individual borrowers. The origin of our business can be traced back to 2011. We are one of the first online individual finance marketplaces in China, according to iResearch, and have built a trusted brand with a demonstrated track record of delivering value to both investors and borrowers. We were the third largest individual finance marketplace in China in terms of transaction volume in the first half of 2018 for mid- to long-term loans, according to iResearch. We strategically focused on facilitating mid- to long-term consumer loans with an average term of 12 months or more, as we believe such loan products are best positioned to generate attractive returns for our investors, and at the same time, capture the financing needs of quality borrowers. With a highly scalable capital-light business model, we have been able to grow our marketplace and reinforce our strengths through network effects.",FINANCE SERVICES,831,2011,,"18th Floor, Building No. 1, Youyou Century Plaza, 428 South Yanggao Road, Pudong New Area, Shanghai 200122, People’s Republic of China",+86 21-6082-8732,http://www.jiayinfintech.cn,Jiayin Group,,$615.25mil,$419.2 mil (last 12 months),$89.0 mil (last 12 months),,JFIN,NASDAQ,3.5,$10.50 - $10.50,$36.8 mil,Roth Capital Partners/ Shenwan Hongyuan Securities,-,5/10/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
52,,"We are a leading U.S. provider of ultra-rugged mobile phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. We currently sell our ruggedized mobile phones and accessories to three of the four largest wireless carriers in the United States—AT&T, Sprint and Verizon—as well as the three largest wireless carriers in Canada—Bell, Rogers and Telus Mobility. Our phones and accessories connect workers with voice, data and workflow applications in two end markets: industrial enterprise and public sector.",TELEPHONE & TELEGRAPH APPARATUS,321,1999,,"1875 South Grant Street, Suite 750, San Mateo, CA 94402, US",(650) 378-8100,http://www.sonimtech.com,Sonim Technologies,,$214.6mil,$135.7 mil (last 12 months),$-8.9 mil (last 12 months),,SONM,NASDAQ,3.6,$11.00 - $11.00,$39.3 mil,Oppenheimer/ Lake Street,National Securities Corporation,5/10/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
53,,"We are a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Our AXA Candidates are generated from our proprietary, human-focused AXA Development Platform and harness the power of endogenous metabolic modulators, or EMMs, a broad family of molecules that fundamentally impact and regulate human metabolism.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),49,2008,,"840 Memorial Drive, Cambridge, MA 02139, US",(857) 320-2200,https://www.axcellahealth.com.,Axcella Health,,$459.8mil,$0 mil (last 12 months),$-36.1 mil (last 12 months),,AXLA,NASDAQ,3.6,$20.00 - $20.00,$71.4 mil,Goldman Sachs/ J.P. Morgan/ SVB Leerink,-,5/9/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
54,,"We are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Our approach is based on the seminal discovery of the presence of Porphyromonas gingivalis, or P. gingivalis, and its secreted toxic virulence factor proteases, called gingipains, in the brains of greater than 90% of more than 100 Alzheimer’s patients observed across multiple studies to date. Additionally, we have observed that P. gingivalis infection causes Alzheimer’s pathology in animal models, and these effects have been successfully treated with a gingipain inhibitor in preclinical studies.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),19,2012,,"269 East Grand Avenue, South San Francisco, CA 94080, US",(415) 910-5717,http://www.cortexyme.com,Cortexyme,,$442.2mil,$0 mil (last 12 months),$-12.5 mil (last 12 months),,CRTX,NASDAQ,4.4,$17.00 - $17.00,$75.0 mil,BofA Merrill Lynch/ Credit Suisse,Canaccord Genuity/ JMP Securities,5/9/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
55,,"We are the leading online recruitment platform in Russia and the Commonwealth of Independent States (“CIS”) and focus on connecting job seekers with employers. We offer potential employers and recruiters paid access to our extensive curriculum vitae (“CV”) database and job postings platform. We also provide both job seekers and employers with a broad range of human resource (“HR”) value added services (“VAS”). Our brand and the strength of our platform allow us to generate significant traffic, over 88% of which was free for us as of December 31, 2017 according to our internal data, and we were the sixth most visited job and employment website globally as of December 31, 2017, according to the latest available data from SimilarWeb. Our CV database contained 19.2 million, 23.0 million and 27.4 million CVs as of December 31, 2015, 2016 and 2017, respectively, and our platform hosted a daily average of more than 304,000, 363,000 and 416,000 job postings in the years ended December 31, 2015, 2016 and 2017, respectively. For the years ended December 31, 2015, 2016 and 2017, our platform averaged 16.3 million, 16.7 million and 17.8 million unique visitors per month, respectively, according to LiveInternet.",HELP SUPPLY SERVICES,683,2000,,"9/10 Godovikova Street, Moscow, 129085 Russia",+7 495 974-6427,http://www.hh.ru,HeadHunter Group PLC,,$675.0mil,$6117.8 mil (last 12 months),$1032.8 mil (last 12 months),,HHR,NASDAQ,16.3,$13.50 - $13.50,$199.7 mil,Morgan Stanley/ Goldman Sachs/ Credit Suisse/ VTB Capital,BofA Merrill Lynch/ Sberbank CIB,5/9/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
56,,"MEC is a leading U.S.-based value-added manufacturing partner that provides a broad range of prototyping and tooling, production fabrication, coating, assembly and aftermarket components. Our customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military and other end markets. We have developed long-standing relationships with our blue chip customers based upon a high level of experience, trust and confidence. “We Make Things Simple” by providing a diverse set of process offerings and a “one stop shop” for end-to-end solutions with benefits throughout the entire product lifecycle, including front-end collaboration in design and prototyping, product manufacturing, aftermarket components and ancillary supply chain benefits.",METAL FORGING & STAMPINGS,3100,1945,,"715 South Street, Mayville, WS 53050, US",(920) 387-4500,http://www.mecinc.com,Mayville Engineering,,$334.8mil,$354.5 mil (last 12 months),$17.9 mil (last 12 months),,MEC,NYSE,6.3,$17.00 - $17.00,$106.3 mil,Baird/ Citigroup/ Jefferies,UBS Investment Bank/ William Blair,5/9/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
57,,"We are a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker that we designed and are developing as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT, as they occur. PSVT is a rapid heart rate condition that starts and stops without warning, often experienced by patients with symptoms including palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting or anxiety.",PHARMACEUTICAL PREPARATIONS,23,2003,,"1111 Dr. Frederik-Philips Blvd., Suite 420, Montréal, Québec, Canada H4M 2X6",(514) 336-0444,http://www.milestonepharma.com,Milestone Pharmaceuticals,,$354.7mil,$0 mil (last 12 months),$-23.2 mil (last 12 months),,MIST,NASDAQ,5.5,$15.00 - $15.00,$82.5 mil,Jefferies/ Cowen/ Piper Jaffray,Oppenheimer & Co.,5/9/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
58,,"We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.",PHARMACEUTICAL PREPARATIONS,44,2015,,"9000 Virginia Manor Road, Suite 200, Beltsville, MD 20705, US",(240) 399-4900,http://www.nextcure.com,NextCure,,$329.0mil,$0 mil (last 12 months),$-22.8 mil (last 12 months),,NXTC,NASDAQ,5.0,$15.00 - $15.00,$75.0 mil,"Morgan Stanley/ BofAMerrill Lynch, Pierce/ Piper Jaffray",-,5/9/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
59,,"While we may pursue an initial business combination in any sector, we intend to focus our efforts on businesses in the financial technology segment of the broader financial services industry, where we believe our management team’s expertise will provide us with a competitive advantage.",BLANK CHECKS,2,2019,,"767 Fifth Avenue, 9th Floor, New York, NY 10153, US",(646) 446-2700,,South Mountain Merger,,$281.25mil,$0 mil (last 12 months),$0 mil (last 12 months),,SMMCU,NASDAQ,22.5,$10.00 - $10.00,$225.0 mil,Citigroup,-,6/20/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
60,,"We are a leading provider of technology-driven solutions in the defense, intelligence and critical infrastructure markets. We provide technical design and engineering services and software to address our customers’ challenges. We have developed significant expertise and differentiated capabilities in key areas of cybersecurity, intelligence, defense, military training, connected communities, physical infrastructure and mobility solutions.",COMPUTER INTEGRATED SYSTEMS DESIGN,15633,1944,,"5875 Trinity Parkway #300, Centreville, Virginia 20120, US",(703) 988-8500,http://www.parsons.com,Parsons,,$2609.7mil,$3560.5 mil (last 12 months),$222.3 mil (last 12 months),,PSN,NYSE,18.5,$27.00 - $27.00,$500.0 mil,Goldman Sachs/ BofA Merrill Lynch/ Morgan Stanley,Jefferies/ Wells Fargo Securities/ Cowen/ SunTrust Robinson Humphrey/ MUFG/ Scotiabank,5/8/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
61,,"We are a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. We are currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.",PHARMACEUTICAL PREPARATIONS,16,2011,,"195 Church Street, 14th Floor, New Haven, CT 06510, US",(203) 304-2499,http://www.trevitherapeutics.com,Trevi Therapeutics,,$177.7mil,$0 mil (last 12 months),$-25.6 mil (last 12 months),,TRVI,NASDAQ,5.5,$10.00 - $10.00,$55.0 mil,SVB Leerink/ Stifel/ BMO Capital Markets,Needham & Company,5/7/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
62,,"We are a bank holding company headquartered in Alexandria, Louisiana. Through our wholly owned subsidiary, Red River Bank, a Louisiana state-chartered bank, we provide a fully integrated suite of banking products and services tailored to the needs of our commercial and retail customers. We operate from a network of 23 banking centers throughout the state and one loan production office in Covington, Louisiana. Banking centers are located in the following markets: Central Louisiana, which includes the Alexandria MSA; Northwest Louisiana, which includes the Shreveport-Bossier City MSA; Southeast Louisiana, which includes the Baton Rouge MSA; and Southwest Louisiana, which includes the Lake Charles MSA. As of December 31, 2018, we were the fifth largest financial institution headquartered in Louisiana based on assets, with total assets of $1.86 billion, total loans of $1.33 billion, total deposits of $1.65 billion, and total stockholders’ equity of $193.7 million.",STATE COMMERCIAL BANKS,320,1998,,"1412 Centre Court Drive, Suite 402, Alexandria, LA 71301, US",(318) 561-5028.,http://www.redriverbank.net,Red River Bancshares,,$324.45mil,$69.2 mil (last 12 months),$23.6 mil (last 12 months),,RRBI,NASDAQ,0.6,$45.00 - $45.00,$27.0 mil,FIG Partners/ Stephens,-,5/3/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
63,,"We are a leading developer and publisher of digital games on mobile and web platforms. Our total revenue has grown from $168.8 million in 2015 to $416.2 million in 2018, representing a compound annual growth rate, or CAGR, of 35%. The mobile portion of our revenue has grown from $109.4 million in 2015 to $323.3 million in 2018, representing a CAGR of 44%. According to data from Eilers & Krejcik, the average CAGR for mobile revenue in the social casino industry was 25% over the same period. We create our games around compelling user experiences, often using authentic land-based content from Scientific Games to anchor these experiences. Our first social game, Jackpot Party Casino, has continued to grow since its launch in 2012, with many of the players who began playing in 2012 still playing six years later. During the fourth quarter of 2018, our games were played by a total of more than 11.6 million players. Of those players, more than 8.4 million played each month, with approximately 32% of the monthly players playing every day, for an average of 54 minutes each day. During that same quarter, according to Eilers & Krejcik, we achieved an 8.6% share of the mobile social casino market and our revenue growth was 5.5 times as high as the social casino market average.",COMPUTER PROCESSING & DATA PREPARATION,390,2016,,"6601 Bermuda Road, Las Vegas, NV 89119, US",(702) 897-7150,http://www.sciplay.com,SciPlay,,$2020.3mil,$416.2 mil (last 12 months),$39.0 mil (last 12 months),,SCPL,NASDAQ,22.0,$16.00 - $16.00,$352.0 mil,BofA Merrill Lynch/ J.P. Morgan/ Deutsche Bank Securities,Goldman Sachs/ Morgan Stanley/ Macquarie Capital/ RBC Capital Markets/ Stifel/ Wedbush Securities,5/3/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
64,,"Beyond Meat is one of the fastest growing food companies in the United States, offering a portfolio of revolutionary plant-based meats. We build meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional benefits of eating our plant-based meat products. Our brand commitment, “Eat What You Love,” represents a strong belief that by eating our plant-based meats, consumers can enjoy more, not less, of their favorite meals, and by doing so, help to address concerns related to human health, climate change, resource conservation and animal welfare.",FOOD & KINDRED PRODUCTS,383,2011,,"1325 East El Segundo Blvd., El Segundo, CA 90245, US",(866) 756-4112,http://www.beyondmeat.com,Beyond Meat,,$1457.5mil,$87.9 mil (last 12 months),$-29.9 mil (last 12 months),,BYND,NASDAQ,9.6,$25.00 - $25.00,$240.6 mil,Goldman Sachs/ J.P. Morgan/ Credit Suisse,BofA Merrill Lynch/ Jefferies/ William Blair,5/2/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
65,,"Our business model comprises three integrated components: (i) our original, reliable and professional content and its distribution through major social media networks and our targeted media platforms in China, (ii) our highly engaged social community characterized by signature user-generated content, and (iii) our transparent and user-friendly online reservation services for medical aesthetic treatment. With reliable and comprehensive content, as well as a multitude of social functions on our platform, users seeking medical aesthetic treatment can discover products and services, evaluate their quality, and reserve desired treatment.",COMPUTER PROCESSING & DATA PREPARATION,862,2014,,"3/F, Wangjing SOHO-Tower 3A, Chaoyang District, Beijing, 100102, People’s Republic of China",+86 10 5707-6564,http://www.soyoung.com,So-Young International,,$1383.4mil,$89.8 mil (last 12 months),$-2.1 mil (last 12 months),,SY,NASDAQ,13.0,$13.80 - $13.80,$179.4 mil,Deutsche Bank Securities/ CICC,-,5/2/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
66,,We are a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.,ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS,92,1998,,"200 Minuteman Road. Andover, MA 01810, US",(978) 552-0900,http://www.transmedics.com,TransMedics Group,,$323.8mil,$13.0 mil (last 12 months),$-23.8 mil (last 12 months),,TMDX,NASDAQ,5.7,$16.00 - $16.00,$91.0 mil,Morgan Stanley/ J.P. Morgan,Cowen and Company/ Canaccord Genuity,5/2/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
67,,"We formed our company in 2012 to acquire and actively manage a portfolio of mineral and royalty interests in the core of what we view as the most active, highly economic, liquids-rich resource basins across the continental United States. Our primary business objective is to maximize risk-adjusted total return to our shareholders by both capturing growth in free cash flow from the continued development of our existing portfolio of 11,648 undeveloped horizontal drilling locations unburdened by development capital expenditures or lease operating expenses, as well as leveraging our highly experienced technical evaluation team to continue to execute upon our scalable business model of sourcing, methodically evaluating and integrating accretive minerals acquisitions in the core of top-tier, liquids-rich resource plays.",CRUDE PETROLEUM & NATURAL GAS,30,2012,,"5914 W. Courtyard Drive, Suite 100, Austin, TX 78730, US",(512) 220-6350,http://www.brighamminerals.com,Brigham Minerals,,$874.8mil,$62.3 mil (last 12 months),$33.4 mil (last 12 months),,MNRL,NYSE,14.5,$18.00 - $18.00,$261.0 mil,Credit Suiss/ Goldman Sachs/ Barclays/ RBC Capital Markets/ UBS Investment Bank/ Wells Fargo Securities,"Raymond James/ Seaport Global Securities/ Simmons Energy/ Tudor, Pickering, Holt (A Division of Piper Jaffray)",4/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
68,,"We are a leading distributor of premium vaporization products and consumption accessories in the United States and have a growing presence in Canada. Our customers include over 6,600 independent smoke shops and regional retail chain stores, which we estimate collectively operate approximately 9,700 retail locations, and hundreds of licensed cannabis cultivators, processors and dispensaries. We also own and operate two of the most visited North American direct-to-consumer e-commerce websites in the vaporization products and consumption accessories industry, VaporNation.com and VapeWorld.com, which offer convenient, flexible shopping solutions directly to consumers.",WHOLESALE-DURABLE GOODS,256,2018,,"1095 Broken Sound Parkway, Suite 300, Boca Raton, FL 33487, US",(877) 292-7660,http://256www.gnln.com,Greenlane Holdings,,$1607.3mil,$178.9 mil (last 12 months),$-5.9 mil (last 12 months),,GNLN,NASDAQ,6.0,$17.00 - $17.00,$102.0 mil,Cowen and Company/ Canaccord Genuity,Ladenburg Thalmann/ Roth Capital Partners/ Northland Securities,4/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
69,,"We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on our proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our “off-the-shelf” technologies, VaxWave and TheraT, to elicit directly within patients a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against infectious diseases and cancers. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels previously not achieved by other published immunotherapy approaches. Our lead infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Our lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers.",PHARMACEUTICAL PREPARATIONS,60,2011,,"350 Fifth Avenue, 72nd Floor, New York, NY 10118, US",+43 1 890 63 60,http://www.hookipapharma.com,HOOKIPA Pharma,,$302.2mil,$7.6 mil (last 12 months),$-16.2 mil (last 12 months),,HOOK,NASDAQ,6.0,$14.00 - $14.00,$84.0 mil,BofA Merrill Lynch/ SVB Leerink/ RBC Capital Markets,Kempen,4/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
70,,"Pinterest is where more than 250 million people around the world go to get inspiration for their lives. They come to discover ideas for just about anything you can imagine: daily activities like cooking dinner or deciding what to wear, major commitments like remodeling a house or training for a marathon, ongoing passions like fly fishing or fashion and milestone events like planning a wedding or a dream vacation. We call these people Pinners. We show them visual recommendations, which we call Pins, based on their personal taste and interests. They then save and organize these recommendations into collections, called boards. Browsing and saving visual ideas on our service helps Pinners imagine what their future could look like, which helps them go from inspiration to reality.","COMPUTER PROGRAMMING, DATA PROCESSING",1797,2008,,"505 Brannan Street, San Francisco, CA 94107, US",(415) 762-7100,,Pinterest,,$10058.1mil,$755.9 mil (last 12 months),$-62.97 mil (last 12 months),,PINS,NYSE,75.0,$19.00 - $19.00,$1425.0 mil,Goldman Sachs/ J.P. Morgan/ Allen & Company,BofA Merrill Lynch/ Barclays/ Citigroup/ Credit Suisse/ Deutsche Bank Securities/ RBC Capital Markets/ Baird/ UBS Investment Bank/ Wells Fargo Securities,4/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
71,,"We provide a video-first communications platform that delivers happiness and fundamentally changes how people interact. We connect people through frictionless video, voice, chat and content sharing and enable face-to-face video experiences for thousands of people in a single meeting across disparate devices and locations. Our cloud-native platform delivers reliable, high-quality video that is easy to use, manage and deploy, provides an attractive return on investment, is scalable and easily integrates with physical spaces and applications. We believe that rich and reliable communications lead to interactions that build greater empathy and trust. We strive to live up to the trust our customers place in us by delivering a communications solution that “just works.” Our goal is to make Zoom meetings better than in-person meetings.","COMPUTER PROGRAMMING, DATA PROCESSING, ETC.",1702,2011,,"55 Almaden Boulevard, 6th Floor San Jose, CA 95113, US",(888) 799-9666,,Zoom Video Communications,,$9230.0mil,$330.5 mil (last 12 months),$0 mil (last 12 months),,ZM,NASDAQ,20.9,$36.00 - $36.00,$751.3 mil,Morgan Stanley/ J. P. Morgan/ Goldman Sachs/ Credit Suisse,BofA Merriil Lynch/ RBC Capital Markets/ Wells Fargo Securities/ JMP Securities/ KeyBanc Capital Markets/ Piper Jaffray/ Stifel/ William Blair,4/18/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
72,,"We are a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Our internally developed and wholly owned pipeline of next-generation tyrosine kinase inhibitors (TKIs) targets numerous genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. The pervasive challenges of intrinsic and acquired treatment resistance often limit the response rate and durability of existing therapies.",PHARMACEUTICAL PREPARATIONS,50,2013,,"10628 Science Center Drive, Ste. 225, San Diego, CA 92121, US",(858) 926-5251,http://www.tptherapeutics.com,Turning Point Therapeutics,,$533.8mil,$0 mil (last 12 months),$-24.8 mil (last 12 months),,TPTX,NASDAQ,9.3,$18.00 - $18.00,$166.5 mil,Goldman Sachs/ SVB Leerink/ Wells Fargo Securities,Canaccord Genuity,4/17/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
73,,"We are the leading pan-African e-commerce platform. Our platform consists of our marketplace, which connects sellers with consumers, our logistics service, which enables the shipment and delivery of packages from sellers to consumers, and our payment service, which facilitates transactions among participants active on our platform in selected markets. We are active in six regions in Africa, which consist of 14 countries that together accounted for 72% of Africa’s GDP of €2 trillion, and 74% of African consumer expenditure of €1.4 trillion in 2018, according to the IMF and Euromonitor, respectively. Though still nascent, we believe that e-commerce in Africa is well positioned to grow. In 2018, less than 1% of retail sales for countries measured in our footprint in Africa were conducted online, compared to nearly 24% in China, according to Euromonitor.",CATALOG & MAIL-ORDER HOUSES,5128,2012,,"Charlottenstraße 4, 10969 Berlin, Germany",+49 (30) 398 20 34 51,,Jumia,,$1109.4mil,$149.6 mil (last 12 months),$-195.2 mil (last 12 months),,JMIA,NYSE,13.5,$14.50 - $14.50,$195.8 mil,Morgan Stanley/ Citigroup/ Berenberg/ RBC Capital Markets,Raymond James/ Stifel/ William Blair,4/12/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
74,,"PagerDuty acts as the central nervous system for the digital enterprise. PagerDuty harnesses digital signals from virtually any software-enabled system or device, combines it with human response data, and orchestrates teams to take the right actions in real time. Our products help organizations improve operations, accelerate innovation, increase revenue, mitigate security risk, and deliver great customer experience. Companies across every industry are undergoing digital transformation in response to their customers’ changing needs. Consumers want to have food delivered to their home from the restaurant of their choice within an hour, to stream a movie on an iPhone while waiting in line at the airport, and to do their holiday shopping from the couch with a few clicks, and a car to show up within minutes to take them anywhere they want to go. Businesses need to accept mobile payments from hundreds of thousands of global customers during a product launch, to instantly update software in autonomous cars to prevent accidents, and to reach customers using e-mail, SMS, and phone with evacuation information during an emergency.",PREPACKAGED SOFTWARE,524,2010,,"600 Townsend St., Suite 200, San Francisco, CA 94103, US",(844) 800-3889,http://www.pagerduty.com,PagerDuty,,$1619.144mil,$117.8 mil (last 12 months),$-40.7 mil (last 12 months),,PD,NYSE,9.1,$24.00 - $24.00,$217.7 mil,Morgan Stanley/ J.P. Morgan Securities/ RBC Capital Markets/Allen,KeyBanc Capital Markets/ Piper Jaffray/ William Blair/ BTIG,4/11/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
75,,"We are pioneering a policy-centric approach to security and IT operations. We transform enterprises’ security operations by helping them visualize, define and enforce a unified security policy across complex, heterogeneous IT and cloud environments. Our products govern how individuals, systems and applications are permitted to communicate and provide policy-based security automation, enabling customers to reduce the time to implement complex network changes from days to minutes. Our solutions increase business agility, eliminate errors from manual processes and ensure continuous compliance through a single console. Since our inception, our solutions have been purchased by over 2,000 customers in over 70 countries, including approximately 15% of the Global 2000.",COMPUTER INTEGRATED SYSTEMS DESIGN,424,2005,,"5 Shoham Street, Ramat-Gan 52521, Israel",+972 (3) 612-8118,http://www.tufin.com,Tufin Software Technologies Ltd.,,$454.1mil,$85.0 mil (last 12 months),$-4.3 mil (last 12 months),,TUFN,NYSE,7.7,$14.00 - $14.00,$107.8 mil,J.P. Morgan/ Barclays Capital/ Jefferies,Oppenheimer/ Piper Jaffray/ Stifel/ William Blair,4/11/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
76,,"The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z® that replenishes and restores the macular protective pigment. A depleted macular protective pigment is a modifiable risk factor for retina-based diseases such as age-related macular degeneration (“AMD”), computer vision syndrome (“CVS”) and diabetic retinopathy. This risk may be modified by taking Lumega-Z to maintain a healthy macular protective pigment. Additional research has also shown a depleted macular protective pigment to be a biomarker for neurodegenerative diseases such as Alzheimer’s disease and dementia.",PHARMACEUTICAL PREPARATIONS,9,2009,,"15150 Avenue of Science, Suite 200, San Diego, California 92128, US",858-605-9055,http://www.guardionhealth.com,Guardion Health Sciences,,$88.7mil,$0.94 mil (last 12 months),$-7.8 mil (last 12 months),,GHSI,NASDAQ,1.5,$4.00 - $4.00,$6.0 mil,WallachBeth Capital/ Westpark Capital,-,4/5/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
77,,"We are a medical device company focused on reducing the risk of stroke and its devastating impact. We believe a key to stroke prevention is minimally invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke. We have pioneered a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care. TCAR relies on two novel concepts – minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain – and combines the benefits of innovative endovascular techniques with fundamental surgical principles.",SURGICAL & MEDICAL INSTRUMENTS & APPARATUS,176,2007,,"1213 Innsbruck Drive, Sunnyvale, CA 94089, US",(408) 720-9002,http://www.silkroadmed.com,Silk Road Medical,,$604.6mil,$34.6 mil (last 12 months),$-37.6 mil (last 12 months),,SILK,NASDAQ,6.0,$20.00 - $20.00,$120.0 mil,J.P. Morgan/ BofA Merrill Lynch,BMO Capital Markets/ Stifel,4/4/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
78,,"We are a leader in building and operating electronic marketplaces for our global network of clients across the financial ecosystem. Our network is comprised of clients across the institutional, wholesale and retail client sectors, including many of the largest global asset managers, hedge funds, insurance companies, central banks, banks and dealers, proprietary trading firms and retail brokerage and financial advisory firms, as well as regional dealers. Our marketplaces facilitate trading across a range of asset classes, including rates, credit, money markets and equities. We are a global company serving clients in 62 countries with offices in North America, Europe and Asia.","SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES",919,1998,,"1177 Avenue of the Americas, New York, New York 10036. US",(646) 430-6000,http://www.tradeweb.com,Tradeweb Markets,,$6000.0mil,$657.6 mil (last 12 months),$159.5 mil (last 12 months),,TW,NASDAQ,40.0,$27.00 - $27.00,$1080.0 mil,J.P. Morgan/ Citigroup/ Goldman Sachs/ Morgan Stanley​,BofA Merrill Lynch/ Barclays/ Credit Suisse/ Deutsche Bank Securities/ UBS Investment Bank/ Wells Fargo Securities/ Jefferies/ Sandler O’Neill + Partners,4/4/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
79,,"We are the largest internet KOL facilitator in China as measured by revenue in 2018 according to the Frost & Sullivan report. We are also China’s largest internet KOL facilitator in e-commerce as measured by the number of online stores and GMV in 2018 and number of signed KOLs and fans as of December 31, 2018 according to the same source. As of December 31, 2018, we had 113 signed KOLs with an aggregate of 148.4 million fans across major social media platforms in China. Through our KOLs, we facilitated the sale of an aggregate GMV of RMB1.2 billion, RMB2.0 billion and RMB2.2 billion on various e-commerce platforms in fiscal years 2017 and 2018 and the first three quarters of fiscal year 2019, respectively. KOLs, also known as influencers, are individuals who have the power to engage and impact people within a specific community or field, such as fashion, culture, entertainment and gaming, and internet KOLs are KOLs who have gained their popularity through the internet.",RETAIL-CATALOG & MAIL-ORDER HOUSES,971,2016,,"4F, Building 1, Blue Collar Garment Industrial Park, 7-1 North Hong Pu Road, Yu Hang District, Hangzhou 311100, People's Republic of China",+86 571-2882 5222,http://www.ruhnn.com,Ruhnn Holding Ltd.,,$1033.9mil,$124.5 mil (last 12 months),$-8.36 mil (last 12 months),,RUHN,NASDAQ,10.0,$12.50 - $12.50,$125.0 mil,Citigroup/ UBS Investment Bank,-,4/3/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
80,,"We are a provider of software application and technology solutions and services to corporate and government customers primarily located in China. We introduced global trade software applications when we launched our operations in 1997 with a vision to make global trade operations easier for our customers. Since our inception, we have continued to innovate by developing technologies that enable us to successfully deliver a series of solutions and services that address the evolving and changing needs of our corporate and government customers. Our mission is to make global trade easier by empowering all players in the ecosystem.",SERVICES-COMPUTER PROGRAMMING SERVICES,299,1997,,"1st Floor, Building D2, Southern Software Park, Tangjia Bay, Zhuhai, Guangdong 519080, China",+86-756-339-5666,http://www.powerbridge.com.,"Powerbridge Technologies Co., Ltd.",,$43.3mil,$22.9 mil (last 12 months),$3.97 mil (last 12 months),,PBTS,NASDAQ,1.8,$5.00 - $5.00,$8.8 mil,Maxim Group/ The Benchmark Company,-,4/2/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
81,,"Lyft started a movement to revolutionize transportation. In 2012, we launched our peer-to-peer marketplace for on-demand ridesharing and have continued to pioneer innovations aligned with our mission. Today, Lyft is one of the largest and fastest-growing multimodal transportation networks in the United States and Canada. To date, we have facilitated over one billion rides.",LOCAL & SUBURBAN TRANSIT & INTERURBAN HWY PASSENGER TRAINS,4791,2007,,"185 Berry Street, Suite 5000, San Francisco, CA 94107",(844) 250-2773,http://www.lyft.com,Lyft,,$20583.1mil,$2156.6 mil (last 12 months),$-911.3 mil (last 12 months),,LYFT,NASDAQ,32.5,$72.00 - $72.00,$2340.0 mil,J.P. Morgan/ Credit Suisse/ Jefferies/ UBS Securities/ Stifel/ RBC Capital Markets/ KeyBanc Capital Markets,Cowen/Raymond James/ Canaccord Genuity/ Evercore ISI/ Piper Jaffray/ JMP Securities/ Wells Fargo Securities/ KKR/ Academy Securities/ Blaylock Van/ Penserra/Siebert Cisneros/ The Williams Capital Group/ CastleOak Securities/ C.L. King & Associates/ Drexel Hamilton/ Great Pacific Securities/ Loop Capital Markets/ Mischler Financial Group/ Samuel A. Ramirez/ R. Seelaus/ Tigress Financial Partners,3/29/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
82,,"We are an iconic American company with a rich history of profitable growth, quality, innovation and corporate citizenship. Our story began in San Francisco, California in 1853 as a wholesale dry goods business. We invented the blue jean 20 years later. Today we design, market and sell products that include jeans, casual and dress pants, tops, shorts, skirts, jackets, footwear and related accessories for men, women and children around the world under our Levi’s, Dockers, Signature by Levi Strauss & Co. and Denizen brands. With $5.6 billion in net revenues and sales in more than 110 countries in fiscal year 2018, we are one of the world’s leading apparel companies with the Levi’s brand having the highest brand awareness in the denim bottoms category globally.",APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL,14400,1853,,"1155 Battery Street San Francisco, CA 94111, US",415-501-6000,http://www.levistrauss.com,Levi Strauss & Co.,,$6553.3mil,$5575.44 mil (last 12 months),$283.1 mil (last 12 months),,LEVI,NYSE,36.7,$17.00 - $17.00,$623.3 mil,Goldman Sachs/ J.P. Morgan,BofA Merrill Lynch/ Morgan Stanley/ Evercore ISI/ BNP PARIBAS / Citigroup/ Guggenheim Securities/ HSBC/ Drexel Hamilton/ Telsey Advisory Group/ The Williams Capital Group,3/21/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
83,,"We are a leading online brokerage firm focusing on global Chinese investors. We are the largest online broker focusing on global Chinese investors in terms of U.S. securities trading volume, with a market share of approximately 58.4% in 2017, according to the iResearch Report. Our proprietary trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives around the world. Our continuous focus on offering innovative products and services and a superior user experience has enabled us to become one of the most utilized and well-recognized online trading platforms for Chinese investors around the world.","SECURITY BROKERS, DEALERS & FLOTATION COMPANIES",446,2014,,"18/F, Grandyvic Building, No. 1 Building, No. 16 Taiyanggong Middle Road, Chaoyang District, Beijing, 100020 PRC",+86-10-56216660.,http://www.itiger.com,UP Fintech Holding Limited,,$1062.3mil,$33.6 mil (last 12 months),$-43.2 mil (last 12 months),,TIGR,NASDAQ,13.0,$8.00 - $8.00,$104.0 mil,Citigroup/ Deutsche Bank Securities,AMTD/ China Merchants Securities (HK)/ Tiger Brokers,3/20/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
84,,"We are an advanced technology company transforming the investing experience by offering a fully digitized brokerage platform. Technology permeates every part of our business, allowing us to offer a redefined user experience built upon an agile, stable, scalable and secure platform. We primarily serve the emerging affluent Chinese population, pursuing a massive opportunity to facilitate a once-in-a-generation shift in the wealth management industry and build a digital gateway into broader financial services.","SECURITY BROKERS, DEALERS & FLOTATION COMPANIES",585,2012,,"11/F, Bangkok Bank Building, No. 18 Bonham Strand W, Sheung Wan, Hong Kong S.A.R., People’s Republic of China",+852 2523-3588,http://www.futuholdings.com,Futu Holdings Limited,,$1332.5mil,$103.6 mil (last 12 months),$17.8 mil (last 12 months),,FHL,NASDAQ,7.5,$12.00 - $12.00,$90.0 mil,Goldman Sachs (Asia)/ UBS Investment Bank/ Credit Suisse,HSBC/ BOCI,3/8/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
85,,"We are a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. We aim to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through our differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which we refer to as intravascular lithotripsy (“IVL”). Our IVL system (our “IVL System”), which leverages our IVL technology (our “IVL Technology”), is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.",SURGICAL & MEDICAL INSTRUMENTS & APPARATUS,162,2009,,"5403 Betsy Ross Drive, Santa Clara, CA 95054, US",(510) 279-4262,http://www.shockwavemedical.com,ShockWave Medical,,$457.4mil,$12.26 mil (last 12 months),$-41.1 mil (last 12 months),,SWAV,NASDAQ,5.7,$17.00 - $17.00,$96.9 mil,Morgan Stanley/ BofA Merrill Lynch,Wells Fargo Securities/ Canaccord Genuity,3/7/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
86,,"We are a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health. We have built a human-centric proprietary product platform for discovery and development that we believe will enable the rapid advancement of a broad portfolio of novel product candidates into non-IND human clinical studies under regulations supporting research with food. Our product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),118,2015,,"65 Hayden Avenue, Lexington, MA 02421, US",(617) 674-9000,https://www.kaleido.com,Kaleido Biosciences,,$444.5mil,$0 mil (last 12 months),$-61.7 mil (last 12 months),,KLDO,NASDAQ,5.0,$15.00 - $15.00,$75.0 mil,Goldman Sachs/ J.P. Morgan/ Morgan Stanley,Canaccord Genuity,2/28/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
87,,"We are a leading amateur esports community and content platform offering a personalized experience to the large and underserved global audience of 2.3 billion gamers, as estimated by NewZoo. According to the Electronic Software Association, the avid gamer, identified as individuals who are considered the most frequent gamers, sees gameplay as central to their social life with 55% playing video games to connect with friends and 46% to spend time with family members. Through our proprietary, cloud-based technology platform, we connect our network of gamers, venues and brand partners to enable local, social and competitive esports that can be uniquely broadcast through our platform. We offer daily and season-focused offerings for which amateur competitive gamers establish meaningful connections with each other while improving their skills.",AMUSEMENT & RECREATION SERVICES,46,2014,,"2906 Colorado Ave. Santa Monica, CA 90404, US",(802) 294-2754,http://www.superleague.com,Super League Gaming,,$91.7mil,$1.05 mil (last 12 months),$-20.6 mil (last 12 months),,SLGG,NASDAQ,2.3,$11.00 - $11.00,$25.0 mil,Northland Capital/ Markets Lake Street,National Securities Corporation,2/26/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
88,,"We are a development-stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. We were incorporated in Nevada in May 2017 and have a limited operating history. Our primary asset is a sublicense agreement with Chelexa pursuant to which Chelexa has granted us an exclusive sublicense to use its BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The license enables us to develop the platform for any indications in humans. Our initial focus will be on the treatment of eczema through the application of a topical cream.",PHARMACEUTICAL PREPARATIONS,2,2017,,"1 Rockefeller Plaza, Suite 1039, New York, NY 10020, US",(646) 756-2997,http://www.hoththerapeutics.com,Hoth Therapeutics,,$52.77mil,$0 mil (last 12 months),$-1.9 mil (last 12 months),,HOTH,NASDAQ,1.3,$5.60 - $5.60,$7.0 mil,Laidlaw & Company (UK) Ltd.,-,2/15/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
89,,"We are a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Our proprietary Avedro Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions, which are caused by changes in the shape of the eye that prevent light from focusing on the retina, causing blurred vision.",PHARMACEUTICAL PREPARATIONS,122,2002,,"201 Jones Road, Waltham, MA 02451, US",(781) 768-3400,http://www.avedro.com,Avedro,,$255.9mil,$24.0 mil (last 12 months),$-25.4 mil (last 12 months),,AVDR,NASDAQ,5.0,$14.00 - $14.00,$70.0 mil,BofA Merrill Lynch/ J.P. Morgan,Cowen/ Guggenheim Securities/ SVB Leerink,2/14/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
90,,"We are an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. Our proprietary TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex, which we believe is essential for T cell therapies to be effective in patients with solid tumors.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),45,2015,,"100 Binney Street, Suite 710, Cambridge, MA 02142, US",(617) 949-5200,http://www.tcr2.com,TCR2 Therapeutics,,$347.8mil,$0 mil (last 12 months),$-20.6 mil (last 12 months),,TCRR,NASDAQ,5.0,$15.00 - $15.00,$75.0 mil,Jefferies/ Leerink Partners/ BMO Capital Markets,Wedbush PacGrow/ China Renaissance,2/14/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
91,,"We are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using our proprietary TriTAC platform, we are developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),45,2015,,"4000 Shoreline Court, Suite 250, South San Francisco, CA 94080, US",(650) 443-7400,http://www.harpoontx.com,Harpoon Therapeutics,,$334.7mil,$4.4 mil (last 12 months),$-22.8 mil (last 12 months),,HARP,NASDAQ,5.4,$14.00 - $14.00,$75.6 mil,Citigroup/ SVB Leerink,Canaccord Genuity/ Wedbush PacGrow,2/8/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
92,,"We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),78,2013,,"151 Oyster Point Boulevard, Suite 300, South San Francisco, CA 94080, US",415-231-5660,http://www.alector.com,Alector,,$1298.9mil,$21.6 mil (last 12 months),$-44.7 mil (last 12 months),,ALEC,NASDAQ,9.3,$19.00 - $19.00,$175.8 mil,Morgan Stanley/ BofA Merrill Lynch/ Cowen/ Barclays,-,2/7/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
93,,"We are an integrated gas-to-power company that seeks to use “stranded” natural gas to satisfy the world’s large and growing power needs. Our mission is to provide modern infrastructure solutions to create cleaner, reliable energy while generating a positive economic impact worldwide. Our business model is simple, yet, we believe, unique for the LNG industry. We aim to deliver targeted energy solutions to customers around the world, thereby reducing their energy costs and diversifying their energy resources, while also reducing pollution and generating compelling margins.",NATURAL GAS DISTRIBUTION,147,2018,,"111 W. 19th Street, 8th Floor, New York, NY 10011, US",(516) 268-7400,http://www.newfortressenergy.com,New Fortress Energy,,$3046.6mil,$106.2 mil (last 12 months),$-55.7 mil (last 12 months),,NFE,NASDAQ,20.0,$14.00 - $14.00,$280.0 mil,Morgan Stanley/ Barclays/ Citigroup/ Credit Suisse,Evercore ISI/ Allen & Company/ JMP Securities/ Stifel,1/31/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
94,,"We provide comprehensive, Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. We help these financial institutions to accelerate their integration into the overseas market by offering complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction and settlement. These financial institutions may “white label” our trading interface (i.e., put their logos on it, make our trading interface available to their customers without referencing our name), or they can select from among our modular functionalities, such as order routing, trade reporting or clearing on specific products or exchanges to offer their customers a comprehensive range of services and products.",PREPACKAGED SOFTWARE,37,2018,,"Room 608A, Air China Century Building, 40 Xiaoyun Road, Chaoyang District, Beijing, 100020 China",+86 010 5617 2312.,http://www.51mm.com,MMTEC,,$79.2mil,$0 mil (last 12 months),$-0.89 mil (last 12 months),,MTC,NASDAQ,1.8,$4.00 - $4.00,$7.2 mil,WestPark Capital,-,1/8/2019,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
95,,"We are a leading digital consumer finance platform and the finance partner of the 360 Group, one of the largest internet companies in China, connecting over one billion accumulated mobile devices. We provide tailored online consumer finance products to prime, underserved borrowers funded primarily by our funding partners. Our proprietary technology platform enables a unique user experience supported by resolute risk management. When coupled with our 360 Group partnership, our technology translates to a meaningful borrower acquisition, borrower retention and funding advantage, supporting the rapid growth and scaling of our business. From inception to September 30, 2018, we had facilitated over RMB94.4 billion (US$14.3 billion) in loans to 6.4 million of our borrowers.",FINANCE SERVICES,691,2016,,"China Diamond Exchange Center, Building B, No. 555 Pudian Road, No. 1701 Century Avenue, Pudong New Area, Shanghai 200122, People's Republic of China",+86 21 6151-6360,http://www.360jie.com.cn,360 Finance,,$2372.9mil,$149.8 mil (last 12 months),$-96.7 mil (last 12 months),,QFIN,NYSE,3.1,$16.50 - $16.50,$51.2 mil,Citigroup/ Haitong International,AMTD/ Lighthouse Capital/ China Securities International/ TF International/ HeungKong Financial/ North Beta Capital,12/14/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
96,,"We are the largest online music entertainment platform in China, operating the top four music mobile apps in terms of mobile MAUs in the second quarter of 2018. Our platform comprises our online music, online karaoke and music-centric live streaming products, supported by our content offerings, technology and data. Our platform is an all-in-one music entertainment destination that allows users to seamlessly engage with music in many ways, including discovering, listening, singing, watching, performing and socializing. On our platform, social interactions such as sharing, liking, commenting, following and virtual gifting, are deeply integrated in our products and highly complementary to the core music experience, thereby enhancing our user experience, engagement and retention.",RADIO BROADCASTING STATIONS,2559,1998,,"17/F, Malata Building, Kejizhongyi Road, Midwest District of Hi-tech Park, Nanshan District, Shenzhen, 518057, the People’s Republic of China",+86-755-8601-3388,http://www.qq.com,Tencent Music Entertainment Group,,$21260.9mil,$2492.6 mil (last 12 months),$470.4 mil (last 12 months),,TME,NASDAQ,82.0,$13.00 - $13.00,$1066.0 mil,Morgan Stanley/ Goldman Sachs (Asia)/ J.P. Morgan/ Deutsche Bank Securities/ BofA Merrill Lynch,Credit Suisse/ CICC/ Allen & Company/ BOCI/ China Renaissance/ HSBC/ KeyBanc Capital Markets/ Stifel,12/12/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
97,,"Messenger RNA, or mRNA, transfers the information stored in our genes to the cellular machinery that makes all the proteins required for life. Our genes are stored as sequences of DNA which contain the instructions to make specific proteins. DNA serves as a hard drive, safely storing these instructions in the nucleus until they are needed by the cell. We see mRNA functioning as the “software of life.” Every cell uses mRNA to provide real time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),680,2009,,"200 Technology Square Cambridge, MA 02139, US",(617) 714-6500,http://www.modernatx.com,Moderna,,$7565.8mil,$191.6 mil (last 12 months),$-299.2 mil (last 12 months),,MRNA,NASDAQ,26.3,$23.00 - $23.00,$604.3 mil,Morgan Stanley/ Goldman Sachs/ J.P. Morgan,"BofA Merrill Lynch/ Barclays/ Piper Jaffray/ Bryan, Garnier/ Oddo BHF/ Oppenheimer/ Needham/ Chardan",12/7/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
98,,"We are a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Our proprietary, first-of-its kind platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, which we refer to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by our new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. Our lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer, or NK, cells without causing vascular leak syndrome, or VLS, observed with approved recombinant IL-2 (aldesleukin).",PHARMACEUTICAL PREPARATIONS,25,2014,,"11099 N. Torrey Pines Road, Suite 290, La Jolla, CA 92037, US",(858) 750-4700,http://www.synthorx.com,Synthorx,,$332.5mil,$0 mil (last 12 months),$-30.6 mil (last 12 months),,THOR,NASDAQ,11.9,$11.00 - $11.00,$131.0 mil,Jefferies/ Leerink Partners/ Evercore ISI,H.C. Wainwright & Co.,12/7/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
99,,"We are a leading online fashion and lifestyle destination in China. We provide young people with a more accessible and enjoyable shopping experience for everyday fashion, particularly as they increasingly live their lives online. People shop not only to buy, but also for leisure, entertainment and to stay informed of the latest trends. Through innovative use of content, our platform provides a vibrant and dynamic community for people to discover and share the latest fashion trends with others, and offers our users a truly comprehensive shopping experience.",BUSINESS SERVICES,1000,2011,,"Zheshang Wealth Center, 12/F, Building No. 1, No. 99 Gudun Road, Xihu District, Hangzhou, 310012, People’s Republic of China.",+86 571 8605-2790,http://www.mogu-inc.com,MOGU,,$1326.7mil,$141.1 mil (last 12 months),$-94.4 mil (last 12 months),,MOGU,NYSE,4.8,$14.00 - $14.00,$66.5 mil,Morgan Stanley/ Credit Suisse/ China Renaissance Securities,-,12/6/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
100,,"Medalist Diversified REIT, Inc. was formed in 2015 as a Maryland corporation, to acquire, reposition, renovate, lease and manage income-producing properties, with a primary focus on (i) commercial properties, including flex-industrial, and retail properties, and (ii) multi-family residential properties. We invest primarily in properties across secondary and tertiary markets in the southeastern part of the United States, with a concentration in Virginia, North Carolina, South Carolina, Georgia, Florida and Alabama. Beginning with our taxable year ended December 31, 2017, we believe that we have operated in a manner qualifying us as a REIT, and we intend to elect to be taxed as a REIT for federal income tax purposes incident to the filing of our federal income tax return. We are externally managed and advised by Medalist Fund Manager, Inc., a Virginia corporation, or our Manager. Our Manager makes all investment decisions for us. Our Manager is owned fifty percent each by Mr. Bill Elliott and Mr. Tim Messier, who are co-Presidents thereof.",REAL ESTATE INVESTMENT TRUSTS,0,2015,,"11 S. 12th Street, Suite 401 Richmond, VA 23219, US",(804) 344-4435,,Medalist Diversified REIT,,$25.6mil,$1.7 mil (last 12 months),$-0.9 mil (last 12 months),,MDRR,NASDAQ,0.2,$10.00 - $10.00,$24.0 mil,Maxim Group LLC,-,11/28/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
101,,"We are a leading omni-channel automotive marketplace in China, ranking third in terms of both volume and GMV of new automobiles sold in 2017, according to the iResearch report. We believe our innovative approach is disrupting the market structure and driving consumer behavioral change.",BUSINESS SERVICES,679,2016,,"9F, Ruihai Building, No. 21 Yangfangdian Road, Haidian District, Beijing 100038, People’s Republic of China",(+86-10) 6399-8902,,TuanChe Limited,,$253.3mil,$66.2 mil (last 12 months),$-11.1 mil (last 12 months),,TC,NASDAQ,2.6,$7.80 - $7.80,$21.8 mil,Maxim Group/ AMTD Tiger,-,11/20/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
102,,"We are an externally managed specialty finance company focused on lending to middle market companies. We have elected to be regulated as a BDC under the 1940 Act. We are managed by our Advisor, a subsidiary of Bain Capital Credit. Since we commenced operations on October 13, 2016 through September 30, 2018, we have invested approximately $1,727.9 million in aggregate principal amount of debt and equity investments prior to any subsequent exits or repayments. We seek to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including first lien, first lien/last-out, unitranche and second lien debt, investments in strategic joint ventures, equity investments and, to a lesser extent, corporate bonds.",FINANCE,0,2018,,"200 Clarendon Street, 37th Floor, Boston, MA 02116, US",(617) 516-2000,http://www.baincapitalbdc.com,Bain Capital Specialty Finance,,$1029.6mil,$0 mil (last 12 months),$0 mil (last 12 months),,BCSF,NYSE,7.5,$20.25 - $20.25,$151.9 mil,"BofA Merrill Lynch/ Goldman Sachs/ Morgan Stanley/ Citigroup/ Credit Suisse/ Keefe, Bruyette & Woods (A Stifel Company)/ Wells Fargo Securities",Janney Montgomery Scott/ JMP Securities/ Academy Securities,11/15/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
103,,"We are the largest auto-backed financing solution provider in China in terms of loan volume in each of 2015, 2016 and 2017, with a market share of approximately 35% in 2017, according to the Oliver Wyman Report. Our platform connects borrowers, the majority of which are small and micro enterprise owners, with both online investors and institutional funding partners. Established in 2011 by a group of entrepreneurs with backgrounds in small and micro enterprises, we are dedicated to providing small and micro enterprise owners with accessible credit.",FINANCE SERVICES,10794,2011,,"50/F, West Building, Fortune Finance Center, No. 33 Jiefang East Road, Jianggan District, Hangzhou, Zhejiang Province, People’s Republic of China",+86-571-5812-3844,http://www.weidai.com.cn,Weidai Ltd.,,$699.9mil,$417.3 mil (last 12 months),$74.4 mil (last 12 months),,WEI,NYSE,4.5,$10.00 - $10.00,$45.0 mil,Morgan Stanley/ Citigroup,AMTD,11/15/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
104,,"We are a global medical technology company focused on the development and commercialization of our proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress. Our Hi-VNI Technology delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Our Precision Flow systems, which use Hi-VNI Technology, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress in a hospital setting. As of September 30, 2018, more than 1.5 million patients have been treated with our Precision Flow systems, and we have a global installed base of over 12,000 capital units.",SURGICAL & MEDICAL INSTRUMENTS & APPARATUS,298,1999,,"100 Domain Drive, Exeter, NH 03833, US",(866) 410-9986,http://www.vapotherm.com,Vapotherm,,$234.2mil,$41.1 mil (last 12 months),$-38.6 mil (last 12 months),,VAPO,NYSE,4.0,$14.00 - $14.00,$56.0 mil,BofA Merrill Lynch/ William Blair,Canaccord Genuity/ BTIG,11/14/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
105,,"Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the FDA’s 505(b)(2) regulatory pathway. Our business model is to develop proprietary innovative products that fulfill an unmet patient need. We have established a diversified pipeline of eight product candidates in various stages of development. Our corporate strategy is to pursue what we perceive to be low-risk 505(b)(2) candidates where existing published literature, historical clinical trials, or physician usage has established safety or efficacy of the molecule, thereby reducing the incremental clinical burden required for us to bring the product to patients. We intend to focus on product candidates that are currently unapproved or product candidates that we believe will offer innovative and proprietary functional advantages to currently available alternatives.",PHARMACEUTICAL PREPARATIONS,10,2017,,"21925 W. Field Parkway, Suite 235, Deer Park, IL, 60010, US",(847) 787-7361,http://www.etonpharma.com,Eton Pharmaceuticals,,$101.5mil,$0 mil (last 12 months),$-11.1 mil (last 12 months),,ETON,NASDAQ,3.6,$6.00 - $6.00,$21.6 mil,National Securities Corporation,-,11/13/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
106,,"We are a leading home equity loan service provider in China with established business infrastructure. According to the Oliver Wyman report, we are the second largest home equity loan service provider among non-traditional financial institutions in China in terms of outstanding loan principal as of December 31, 2017. We facilitate loans by connecting MSE owners with our funding partners. With more than ten years of experience in the loan service industry, we have established a national network of 73 branches and sub-branches in over 40 cities in China. The extensive local knowledge and resources we have acquired while building our business infrastructure distinguish us from other market players.",FINANCE SERVICES,4250,1999,,"44/F, Tower G, No.16 Zhujiang Dong Road, Tianhe District, Guangzhou City, Guangdong Province 510620, People’s Republic of China",+86 (020) 6231-6688,http://www.cashchina.cn,CNFinance Holdings Limited,,$510.0mil,$595.4 mil (last 12 months),$104.5 mil (last 12 months),,CNF,NYSE,6.5,$7.50 - $7.50,$48.8 mil,Roth Capital Partners/ Shenwan Hongyuan Securities,-,11/7/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
107,,"We are a medical technology company focused on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation, or SNM, solutions. SNM therapy is primarily used to treat patients with overactive bladder, or OAB, fecal incontinence, or FI, and urinary retention, or UR. Our proprietary rechargeable SNM system, or our r-SNM System, delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR.",SURGICAL & MEDICAL INSTRUMENTS & APPARATUS,72,2012,,"26 Technology Drive, Irvine, CA 92618, US",(949) 396-6322,http://www.axonicsmodulation.com,Axonics Modulation Technologies,,$399.6mil,$0.14 mil (last 12 months),$-24.2 mil (last 12 months),,AXNX,NASDAQ,8.0,$15.00 - $15.00,$120.0 mil,BofA Merrill Lynch/ Morgan Stanley,Wells Fargo Securities/ SunTrust Robinson Humphrey,10/31/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
108,,"We are a commercial-stage, fully-integrated biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Our gene therapy approach seeks to transform a patient’s own, or autologous, HSCs into a gene-modified drug product to treat the patient’s disease through a single administration. We achieve this outcome by utilizing a lentiviral vector to introduce a functional copy of a missing or faulty gene into the patient’s autologous HSCs through an ex vivo process, resulting in a drug product that can then be re-introduced into the patient at the bedside.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),100,2015,,"108 Cannon Street, London EC4N 6EU, United Kingdom",+44 (0) 203 384 6700,http://www.orchard-tx.com,Orchard Rx Ltd.,,$1176.7mil,$0 mil (last 12 months),$-193.8 mil (last 12 months),,ORTX,NASDAQ,14.3,$14.00 - $14.00,$200.0 mil,J.P. Morgan/ Goldman Sachs/ Cowen,Wedbush PacGrow,10/31/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
109,,"We are a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost than our competitors.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),221,2013,,"455 Mission Bay Boulevard South, Suite 545, San Francisco, CA 94158, US",(800) 719-0671,http://www.twistbioscience.com,Twist Bioscience,,$372.5mil,$21.0 mil (last 12 months),$-68.4 mil (last 12 months),,TWST,NASDAQ,5.0,$14.00 - $14.00,$70.0 mil,J.P. Morgan/ Cowen,Allen & Company/ Baird,10/31/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
110,,"We are a clinical stage biopharmaceutical company leveraging our proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. While cell therapies have the potential to address a variety of diseases, they are limited by availability of donor cells, matching a donor to the patient, and the decline in donor cell functionality when expanding the cells to achieve a therapeutic dose. We have leveraged our nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. Our proprietary technology is designed to allow for the proliferation of donor cells while maintaining the cells’ functional therapeutic characteristics, which, if approved, will provide a treatment alternative for patients.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),52,1998,,"5 Nahum Heftsadie St., Givaat Shaul, Jerusalem 91340, Israel",+972 (2) 659-5666,http://www.gamida-cell.com,Gamida Cell Ltd.,,$193.8mil,$0 mil (last 12 months),$-30.2 mil (last 12 months),,GMDA,NASDAQ,6.3,$8.00 - $8.00,$50.0 mil,BMO Capital Markets/ RBC Capital Markets,Needham & Company Oppenheimer & Co.,10/26/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
111,,"We operate a leading independent technology platform enabling financial services in China in terms of loan volume facilitated, according to Oliver Wyman. We connect business partners and financial partners on our open platform and enable them to provide financial services to end users efficiently and effectively. We empower our business partners by providing them with the capability to add a financing option to their product offerings. We help our financial partners adapt to the new digital economy by enabling them to access the online population that they could not otherwise reach efficiently or effectively.","COMPUTER PROGRAMMING, DATA PROCESSING",449,2015,,"216, 2/F East Gate, Pacific Century Place, No. A2 Gongti North Road, Chaoyang District, Beijing, People's Republic of China",+86 (10) 8564-3600,http://www.pintec.com,Pintec Technology Holdings,,,$140.5 mil (last 12 months),$0.46 mil (last 12 months),,PT,NYSE,3.7,$11.88 - $11.88,$44.3 mil,Goldman Sachs (Asia)/ Deutsche Bank Securities/ Citigroup,ICBC International,10/25/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
112,,"We are a rapidly growing designer, marketer, and distributor of premium products for the outdoor and recreation market. Our brand promise is to ensure each YETI product will deliver exceptional performance and durability in any environment. By consistently delivering on this promise, we have built a following of passionate and engaged consumers, ranging from serious outdoor enthusiasts to individuals who value products of uncompromising quality and design.",SPORTING & ATHLETIC GOODS,565,2006,,"5301 Southwest Parkway, Suite 200 Austin, TX 78735, US",(512) 394-9384,,YETI Holdings,,$1505.6mil,$726.7 mil (last 12 months),$30.8 mil (last 12 months),,YETI,NYSE,16.0,$18.00 - $18.00,$288.0 mil,BofA Merrill Lynch/ Morgan Stanley/ Jefferies,Baird/ Piper Jaffray/ Citigroup/ Goldman Sachs/ KeyBanc Capital Markets/ William Blair/ Raymond James/ Stifel/ Academy Securities,10/25/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
113,,"We are a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, our proprietary technology platform. Our GeneRide technology is designed to precisely integrate corrective genes into a patient’s genome to provide a stable therapeutic effect. Because GeneRide is designed to have this durable therapeutic effect, we are initially targeting rare liver disorders in pediatric patients where it is critical to provide treatment early in a patient’s life before irreversible disease pathology can occur.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),20,2014,,"610 Main Street, 3rd Floor, Cambridge, MA 02139, US",(617) 245-0399.,http://www.logicbio.com,LogicBio Therapeutics,,$219.38mil,$0 mil (last 12 months),$-15.8 mil (last 12 months),,LOGC,NASDAQ,7.0,$10.00 - $10.00,$70.0 mil,Jefferies/ Barclays/ William Blair,Chardan,10/19/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
114,,"Our mission is to redefine urban mobility and make life better Our vision is to become the number one brand for urban mobility, powered by design and technology. We are the world’s leading provider of smart urban mobility solutions, according to CIC. We have created a new market category—smart electric two-wheeled vehicles—to redefine urban mobility. Before NIU, smart electric two-wheeled vehicles did not exist in China, where two-wheeled vehicles were perceived low-end. We have changed that perception with our smart e-scooters and premium brand “NIU.” We currently design, manufacture and sell high-performance smart e-scooters. We are the largest lithium-ion battery-powered e-scooters company in China and a leader in Europe in terms of sales volume in 2017, according to CIC. As of June 30, 2018, we had sold more than 431,500 smart e-scooters in China, Europe and other countries. According to CIC, in 2017, we led in China’s lithium-ion battery-powered electric two-wheeled vehicles market with market shares of 26.0% and 39.5% in terms of sales volume and sales value, respectively, compared to 6.7% and 7.0% for the number two player, and we ranked third in the European medium-end e-motorcycle market with a market share of 11.1% in terms of sales volume.",MOTOR VEHICLES & PASSENGER CAR BODIES,348,2014,,"No. 10 Wangjing Street, Building A, 11/F, Chaoyang District, Beijing 100102, People's Republic of China",+86 10-6432-1899,http://www.niu.com,Niu Technologies,,$669.0mil,$151.5 mil (last 12 months),$-58.6 mil (last 12 months),,NIU,NASDAQ,7.0,$9.00 - $9.00,$56.0 mil,Credit Suisse/ Citigroup,Needham & Company,10/19/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
115,,"SolarWinds is a leading provider of information technology, or IT, infrastructure management software. Our products give organizations worldwide, regardless of type, size or IT infrastructure complexity, the power to monitor and manage the performance of their IT environments, whether on-premise, in the cloud, or in hybrid models. We combine powerful, scalable, affordable, easy to use products with a high-velocity, low-touch sales model to grow our business while also generating significant cash flow. Our business is focused on building products that enable technology professionals to manage “all things IT.” We continuously engage with technology professionals to understand the challenges they face maintaining high-performing and highly available on-premise, public and private cloud and hybrid IT infrastructures. The insights we gain from engaging with technology professionals allow us to build products that solve well-understood IT management challenges in ways that technology professionals want them solved.",PREPACKAGED SOFTWARE,2540,2015,,"7171 Southwest Parkway, Building 400, Austin, TX 78735, US",(512) 682-9300,http://www.solarwinds.com.,SolarWinds,,$4649.13mil,$627.2 mil (last 12 months),$-405.1 mil (last 12 months),,SWI,NYSE,25.0,$15.00 - $15.00,$387.5 mil,Goldman Sachs/ J.P. Morgan/ Morgan Stanley/ Credit Suisse,Barclays/ Citigroup/ Evercore ISI/ Jefferies/ Macquarie Capital/ BofA Merrill Lynch/ Nomura/ RBC Capital Markets/ JMP Securities/ KeyBanc Capital Markets/ Mischler Financial Group/ Robert W. Baird/ Samuel A. Ramirez/ SunTrust Robinson Humphrey,10/19/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
116,,"We are a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. In 2017, we generated total revenues of $245.7 million across our existing portfolio of promoted specialty neurology and women’s health products, as well as our non-promoted products, which are primarily complex formulations of generic drugs. We recently received regulatory approval from the FDA for M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg) for the treatment of ADHD in patients aged 13 to 65, as well as Osmolex ER (amantadine extended-release tablets) for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions, which are involuntary muscle movements caused by certain medications, in adults. We launched M-72 in the second quarter of 2018 and are preparing to launch Osmolex ER in the second half of 2018. In addition, we have a late-stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: Ontinua ER (arbaclofen extended-release tablets) for muscle spasticity in multiple sclerosis patients and RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid. Many of our products use our proprietary osmotic-release drug delivery system, Osmodex, which we believe offers advantages over alternative extended-release, or ER, technologies.",PHARMACEUTICAL PREPARATIONS,414,2016,,"400 Crossing Boulevard, Bridgewater, NJ 08807, US",(908) 809-1300,http://www.osmotica.com,Osmotica Pharmaceuticals plc,,$360.5mil,$261.7 mil (last 12 months),$-13.7 mil (last 12 months),,OSMT,NASDAQ,6.7,$7.00 - $7.00,$46.6 mil,Jefferies/ Barclays/ RBC Capital MarketsWells/ Fargo Securities,-,10/18/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
117,,"We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. We recently completed a Phase 1 clinical trial of PB2452 in healthy subjects. Our second product candidate, PB1046, is a once-weekly fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension, or PAH. PB1046 utilizes our proprietary half-life extending elastin-like polypeptide, or ELP, technology, which also serves as the engine for our preclinical pipeline. We retain worldwide rights to all of our product candidates.",PHARMACEUTICAL PREPARATIONS,19,2002,,"1 Great Valley Parkway, Suite 30, Malvern, PA 19355, US",(610) 981-6500,http://www.phasebio.com,PhaseBio Pharmaceuticals,,$254.6mil,$0 mil (last 12 months),$-16.2 mil (last 12 months),,PHAS,NASDAQ,9.2,$5.00 - $5.00,$46.0 mil,Citigroup/ Cowen/ Stifel,Needham,10/18/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
118,,"Studio City is a world-class gaming, retail and entertainment resort located in Cotai, Macau. Studio City Casino has 250 mass market gaming tables and approximately 970 gaming machines, which we believe provide higher margins and attractive long-term growth opportunities. The mass market focus of Studio City Casino is complemented with junket and premium direct VIP rolling chip operations, which include 45 VIP rolling chip tables.",HOTELS & MOTELS,5230,2000,,"36/F, The Centrium, 60 Wyndham Street, Central, Hong Kong",+852 2598-3600,http://www.studiocity-macau.com,Studio City International Holdings,,$1154.97mil,$568.1 mil (last 12 months),$-44.3 mil (last 12 months),,MSC,NYSE,28.8,$12.50 - $12.50,$359.4 mil,Deutsche Bank Securities/ Credit Suisse/ Morgan Stanley,Bank of Communications /Macau Branch/ ICBC (Macau) Capital Limited,10/18/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
119,,"We are a medical device company that has pioneered a proprietary minimally invasive surgical implant system, which we call iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Since we introduced iFuse in 2009, more than 34,000 procedures have been performed by over 1,700 surgeons, in the United States and 33 other countries. Published clinical studies have shown that 15% to 30% of all chronic lower back pain is associated with the sacroiliac joint. We believe iFuse is currently used in the majority of minimally invasive surgical fusions of the sacroiliac joint in the United States.",SURGICAL & MEDICAL INSTRUMENTS & APPARATUS,168,2008,,"471 El Camino Real, Suite 101, Santa Clara, CA 95050, US",(408) 207-0700,http://www.si-bone.com,SI-BONE,,$344.9mil,$51.8 mil (last 12 months),$-17.9 mil (last 12 months),,SIBN,NASDAQ,7.2,$15.00 - $15.00,$108.0 mil,Morgan Stanley/ BofA Merrill Lynch,Canaccord Genuity/ JMP Securities,10/17/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
120,,"Anaplan is pioneering the category of Connected Planning, which allows organizations to transform their businesses by making better and faster decisions. We believe Connected Planning is the next essential cloud category. It fundamentally transforms planning by connecting all of the people, data, and plans needed to accelerate business value and enable real-time planning and decision-making in rapidly changing business environments. Connected Planning accelerates business value by transforming the way organizations make decisions and placing the power of planning in the hands of every individual at every level within and between organizations.",PREPACKAGED SOFTWARE,1102,2008,,"50 Hawthorne Street, San Francisco, CA 94105, US",(415) 742-8199.,http://www.anaplan.com,Anaplan,,$2067.9mil,$199.9 mil (last 12 months),$-78.8 mil (last 12 months),,PLAN,NYSE,15.5,$17.00 - $17.00,$248.0 mil,Goldman Sachs/ Morgan Stanley/ Barclays,KeyBanc Capital Markets/ Canaccord Genuity/ Evercore ISI/ JMP Securities/ Needham/ Piper Jaffray/ SunTrust Robinson Humphrey,10/12/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
121,,"We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. This receptor, CD6, plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.",PHARMACEUTICAL PREPARATIONS,7,2017,,"2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037, US",858-412-5302,http://www.equilliumbio.com,Equillium,,$234.5mil,$0 mil (last 12 months),$-4.4 mil (last 12 months),,EQ,NASDAQ,4.7,$14.00 - $14.00,$65.4 mil,Jefferies/ Leerink Partners/ Stifel,-,10/12/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
122,,"We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),70,2017,,"210 East Grand Avenue, South San Francisco, CA 94080, US",(415) 640-5325,http://www.allogene.com,Allogene Therapeutics,,$2074.1mil,$0 mil (last 12 months),$-0.1 mil (last 12 months),,ALLO,NASDAQ,18.0,$18.00 - $18.00,$324.0 mil,Goldman Sachs/ J.P. Morgan/ Cowen/ Jefferies,-,10/11/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
123,,"We are a pure-play, fully integrated lithium company, with a long, proven history of producing performance lithium compounds. Our primary products, namely battery-grade lithium hydroxide, butyllithium and high purity lithium metal, are critical inputs used in various performance applications. Our strategy is to focus on supplying high performance lithium compounds to the fast-growing EV (electric vehicle) battery market, while continuing to maintain our position as a leading global producer of butyllithium and high purity lithium metal. With extensive global capabilities, over 60 years of continuous production experience, applications and technical expertise and deep customer relationships, we believe we are well positioned to capitalize on the accelerating trend of vehicle electrification.",CHEMICALS & ALLIED PRODUCTS,750,2017,,"2929 Walnut Street, Philadelphia, PA, 19104, US",215-299-6000,http://www.livent.com,Livent,,$2431mil,$418.5 mil (last 12 months),$84.8 mil (last 12 months),,LTHM,NYSE,20.0,$17.00 - $17.00,$340.0 mil,BofA Merrill Lynch/ Goldman Sach/ Credit Suisse,Citigroup/ Loop Capital Markets/ Nomura,10/11/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
124,,"Elastic created the Elastic Stack (previously known as the ELK Stack), a powerful set of software products that ingest and store data from any source, and in any format, and perform search, analysis, and visualization in milliseconds or less. Developers build on top of the Elastic Stack to apply the power of search to their data and solve business problems. We have also built software solutions on the Elastic Stack that address a wide variety of use cases including app search, site search, enterprise search, logging, metrics, APM, business analytics, and security analytics. The Elastic Stack and our solutions are designed to run on premises, in public or private clouds, or in hybrid environments. As the technology landscape shifts, our products grow and adapt. In that sense, we believe that our company is truly elastic.",PREPACKAGED SOFTWARE,944,2012,,"800 West El Camino Real, Suite 350, Mountain View, CA 94040, US",(650) 458-2620,http://www.elastic.co,Elastic N.V.,,$2501.7mil,$184.9 mil (last 12 months),$-61.3 mil (last 12 months),,ESTC,NYSE,7.0,$36.00 - $36.00,$252.0 mil,Goldman Sachs/ J.P. Morgan/ Barclays/ RBC Capital Markets,BofA Merrill Lynch/ Citigroup/ Jefferies/ Canaccord Genuity,10/5/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
125,,"We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we have launched our liquid biopsy tests, Guardant360 and GuardantOMNI, for advanced stage cancer, which fuel our programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Guardant360, which we launched in 2014 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 National Comprehensive Cancer Network, or NCCN, Centers, and we believe it is the world’s market leading comprehensive liquid biopsy test based on public disclosure of the number of comprehensive liquid biopsy tests sold in 2017. Precision oncology, as it is practiced today, is primarily focused on matching cancer patients to personalized treatments based on the underlying molecular profile of their tumors",MEDICAL LABORATORIES,348,2011,,"505 Penobscot Drive, Redwood City, CA 94063, US",(855) 698-8887,http://www.guardanthealth.com,Guardant Health,,$1587.6mil,$67.2 mil (last 12 months),$-83.8 mil (last 12 months),,GH,NASDAQ,12.5,$19.00 - $19.00,$237.5 mil,J.P. Morgan/ BofA Merrill Lynch,Cowen/ Leerink Partners/ William Blair,10/4/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
126,,"We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our most advanced product candidate is KSI-301, a biologic therapy built with our antibody biopolymer conjugate platform, or ABC Platform, which is designed to maintain potent and effective drug levels in ocular tissues. We believe that KSI-301, if approved, has the potential to become an important anti-VEGF therapy in wet age-related macular degeneration, or wet AMD, and diabetic retinopathy, or DR. KSI-301 and our ABC Platform were developed at Kodiak, and we own worldwide rights to those assets, including composition of matter patent protection for KSI-301. We have applied our ABC Platform to develop additional product candidates beyond KSI-301, including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate. We intend to progress these and other product candidates to address high-prevalence ophthalmic diseases.",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),28,2009,,"2631 Hanover Street, Palo Alto, CA 94304, US",(650) 281-0850,http://www.kodiak.com,Kodiak Sciences Inc.,,$365.7mil,$0 mil (last 12 months),$-32.48 mil (last 12 months),,KOD,NASDAQ,9.0,$10.00 - $10.00,$90.0 mil,Morgan Stanley/ BofA Merrill Lynch,Barclays/ Chardan,10/4/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
127,,"We operate the largest online global marketplace that enables businesses to find and work with highly skilled freelancers as measured by GSV. Freelancers are an increasingly sought-after, critical and expanding segment of the global workforce. In the 12 months ended June 30, 2018, our platform enabled $1.56 billion of GSV across 2.0 million projects between approximately 375,000 freelancers and 475,000 clients in over 180 countries.",COMPUTER PROCESSING & DATA PREPARATION,395,2013,,"441 Logue Avenue, Mountain View, CA 94043, US",(650) 316-7500,http://www.upwork.com,Upwork,,$1561.2mil,$228.9 mil (last 12 months),$-17.8 mil (last 12 months),,UPWK,NASDAQ,12.5,$15.00 - $15.00,$187.2 mil,Citigroup/ Jefferies/ RBC Capital Markets,Stifel/ JMP Securities,10/3/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
128,,"We are a fast-growing mobile internet company. Sophisticated big data analytics and proprietary AI capability are the backbone of our business. Our global portfolio of mobile applications serves a large global user base comprised of an average of 132.6 million DAUs across more than 240 countries and regions in June 2018, compared to an average of 75.6 million DAUs in June 2017, representing 75.3% year-on-year growth. Our core product, TouchPal Smart Input, is an intelligent input method for mobile devices and generates a massive, diverse set of user interaction data. We employ proprietary AI and big data analytical technologies both to process such data and a large amount of multi-language content that we source and organize from the internet, and to develop advanced multilingual natural language processing and semantic understanding technologies. These technologies enable us to obtain in-depth user insights and identify market opportunities, which set the foundation for developing content-rich mobile applications that deliver relevant content for different verticals such as lifestyle, healthcare and entertainment. We have also built a rich library of user profiles and interests that allows us to grow our user base effectively.",COMPUTER PROCESSING & DATA PREPARATION,385,2008,,"Building 7, No. 2007 Hongmei Road, Xuhui District, Shanghai, 201103, People's Republic of China",+86 21 6485 6352.,http://www.touchpal.com,CooTek (Cayman) Inc.,,$767mil,$78.5 mil (last 12 months),$-3.9 mil (last 12 months),,CTK,NYSE,4.4,$12.00 - $12.00,$52.2 mil,Credit Suisse/ BofA Merrill Lynch/ Citigroup,-,9/28/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
129,,"We are a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. We use our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTACs, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a new therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines.",PHARMACEUTICAL PREPARATIONS,69,2013,,"5 Science Park, 395 Winchester Ave., New Haven, CT 06511, US",(203) 535-1456,http://www.arvinas.com,Arvinas,,$514.5mil,$11.7 mil (last 12 months),$-97.8 mil (last 12 months),,ARVN,NASDAQ,7.5,$16.00 - $16.00,$120.0 mil,Goldman Sachs/ Citigroup/ Piper Jaffray,-,9/27/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
130,,"We are a leading AI company in China that creates and delivers products and services to popularize English learning. Our proprietary AI teacher utilizes cutting-edge deep learning and adaptive learning technologies, big data, well-established education pedagogies and the mobile internet. We believe our innovative approach fundamentally transforms learning. We were named on the list of “The 100 Most Promising Private Artificial Intelligence Companies in the World” for 2018 by CB Insights. We were one of the seven companies from China on the list and the only Chinese company out of the two in the education category globally.",EDUCATIONAL SERVICES,1689,2013,,"3/F, Building B, No. 1687 Changyang Road, Yangpu District, Shanghai, People’s Republic of China",+86 21-3511-7188,http://www.liulishuo.com,LAIX Inc.,,$599.4mil,$52.4 mil (last 12 months),$-54.8 mil (last 12 months),,LAIX,NYSE,5.8,$12.50 - $12.50,$71.9 mil,Morgan Stanley/ Goldman Sachs (Asia),-,9/27/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
131,,"We are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. In June 2018, we completed our 12 month commercial launch period, which included training, production, and staffing for the marketing of the DABRA laser system and disposable catheter, together referred to as DABRA, in the United States.",SURGICAL & MEDICAL INSTRUMENTS & APPARATUS,75,2002,,"2070 Las Palmas Drive, Carlsbad, CA 92011, US",(760) 804-1648,http://www.ramed.com,Ra Medical Systems,,$205.8mil,$5.4 mil (last 12 months),$-15.9 mil (last 12 months),,RMED,NYSE,3.9,$17.00 - $17.00,$66.3 mil,Piper Jaffray/ Cantor,SunTrust Robinson Humphrey/ Nomura/ Maxim Group,9/27/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
132,,"We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our product candidate, vibegron, is an oral, once-daily, small molecule that, based on in vitro data, is a potent and highly selective beta-3 agonist. We are currently evaluating vibegron in our 1,400 patient, international pivotal Phase 3 clinical trial for the treatment of overactive bladder, or OAB. We expect to report top-line results from this clinical trial in the first or second quarter of 2019, and if the results are positive, we plan to submit a new drug application to the U.S. Food and Drug Administration, or FDA, by early 2020.",PHARMACEUTICAL PREPARATIONS,0,2016,,"Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom",+44 203 318 9709,http://www.urovant.com,Urovant Sciences,,$420.4mil,$0 mil (last 12 months),$-64.8 mil (last 12 months),,UROV,NASDAQ,10.0,$14.00 - $14.00,$140.0 mil,J.P. Morgan/ Jefferies/ Cowen,-,9/27/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
133,,"Our mission is to transform the way students learn by delivering high-quality education at scale through technology to private K-12 schools. We provide a complete pedagogical system with technology-enabled features to deliver educational content to private schools in Brazil. Our turnkey curriculum solutions provide educational content in both printed and digital formats delivered through our platform to improve the learning process. Our network as of March 31, 2018 consisted of 1,140 partner schools, compared to 835 schools as of March 31, 2017, 667 schools as of March 31, 2016 and 377 schools as of March 31, 2015, representing annual growth rates of 36.5%, 25.2% and 76.9%, respectively. We had 405,814 enrolled students across all Brazilian states as of March 31, 2018, compared to 322,031 enrolled students as of March 31, 2017, 265,354 as of March 31, 2016 and 156,011 as of March 31, 2015, representing annual growth rates of 26.0%, 21.4% and 70.1%, respectively.",EDUCATIONAL SERVICES,1075,2004,,"Rua Elvira Ferraz 250, Sala 716, Vila Olímpia, São Paulo - SP, 04552-040, Brazil",+55 (85) 3033-8264,http://www.arcoeducacao.com.br,Arco Platform Ltd.,,$850.4mil,$76.9 mil (last 12 months),$14.9 mil (last 12 months),,ARCE,NASDAQ,11.1,$17.50 - $17.50,$194.4 mil,Goldman Sachs/ Morgan Stanley/ Itaú BBA/ BofA Merrill Lynch,Allen & Company/ BTG Pactual/ UBS Investment Bank,9/26/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
134,,"We are Capital Bancorp, Inc., a bank holding company and a Maryland corporation, and we operate primarily through our wholly owned subsidiary, Capital Bank, N.A., a commercial-focused community bank based in the Washington, D.C. and Baltimore metropolitan areas. We serve businesses, not-for-profit associations and entrepreneurs throughout the region by partnering with them to design tailored financial solutions supported by customized technology and “client first” advice. Capital Bank is headquartered in Rockville, Maryland, and operates a branch-lite model through five commercial bank branches, five mortgage offices, two loan production offices, a limited service branch, and three corporate and operations facilities located in key markets throughout our operating area.",NATIONAL COMMERCIAL BANKS,195,1998,,"One Church Street, Rockville, MD 20850, US",(240) 283-0416,http://www.capitalbankmd.com,Capital Bancorp,,$164.5mil,$63.1 mil (last 12 months),$12.7 mil (last 12 months),,CBNK,NASDAQ,2.2,$12.50 - $12.50,$27.9 mil,"Keefe, Bruyette & Woods (A Stifel Company)/ Stephens",Sandler O’Neill + Partners/ Hovde Group,9/26/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
135,,"We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Leveraging our targeted-design platform, we have engineered and developed product candidates that target clinically validated mechanisms in order to address antibiotic resistance. Our lead product candidate, ETX2514, as well as one of our other product candidates, ETX0282, inhibit one of the most prevalent forms of bacterial resistance, b-lactamase enzymes, so-named because of their ability to inactivate b-lactam antibiotics, one of the most commonly used classes of antibiotics. By blocking this resistance mechanism, these product candidates, when administered in combination with b-lactam antibiotics, are designed to restore the efficacy of those antibiotics. Our other product candidate, zoliflodacin, targets the validated mechanism of action of the fluoroquinolone class of antibiotics, but does so in a novel manner to avoid existing fluoroquinolone resistance.",PHARMACEUTICAL PREPARATIONS,34,2018,,"35 Gatehouse Drive, Waltham, MA 0245, US",(781) 810-0120,http://www.entasistx.com,Entasis Therapeutics Holdings,,$208.7mil,$5.0 mil (last 12 months),$-33.9 mil (last 12 months),,ETTX,NASDAQ,5.0,$15.00 - $15.00,$75.0 mil,Credit Suisse/ BMO Capital Markets,SunTrust Robinson Humphrey/ Wedbush PacGrow,9/26/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
136,,"We are a leading global provider of survey software products that enable organizations to engage with their key constituents, including their customers, employees and the markets they serve. SurveyMonkey has changed the way people gather feedback by making it easy for anyone to create their own online surveys. Our mission is to power curious individuals and organizations to measure, benchmark and act on the opinions that drive success. Our People Powered Data platform enables conversations at scale to deliver impactful customer, employee and market insights to our over 16 million active users globally.","COMPUTER PROGRAMMING, DATA PROCESSING",761,1999,,"One Curiosity Way, San Mateo, CA 94403, US",(650) 543-8400,http://www.surveymonkey.com,SVMK (SurveyMonkey),,$1213.9mil,$233.5 mil (last 12 months),$-32.1 mil (last 12 months),,SVMK,NASDAQ,12.0,$12.00 - $12.00,$180.0 mil,J.P. Morgan/ Allen & Company/ BofA Merrill Lynch,Credit Suisse/ UBS Investment Bank/ Wells Fargo Securities/ SunTrust Robinson Humphrey/ CODE Advisors/ Foros. JMP Securities/ LionTree,9/26/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
137,,"We have developed a unique IoT @ Home platform, consisting of an ecosystem of innovative IoT products, together with a suite of complementary consumable products and value-added businesses. This platform provides an attractive entry point into the consumer home, enabling consumers to intelligently interact with a broad portfolio of IoT products in an intuitive and human-like manner to make daily life more convenient, efficient and enjoyable, while allowing us to grow our household user base and capture various additional scenario-driven consumption events in the home environment. As of June 30, 2018, our IoT @ Home platform had over 1.2 million household users.",HOUSEHOLD APPLIANCES,527,2015,,"Wansheng Square, Rm 1302 Tower C, Xingang East Road, Haizhu District, Guangzhou, Guangdong, 510220, People's Republic of China",+86 20 8930 9496,http://www.viomi.com.cn,"Viomi Technology Co., Ltd.",,$623.4mil,$241.4 mil (last 12 months),$21.3 mil (last 12 months),,VIOT,NASDAQ,11.4,$9.00 - $9.00,$102.6 mil,Morgan Stanley/ CICC,Needham & Company,9/25/2018,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
